Isfahan Cardiovascular Research Institute
P.O Box: 81465-1148
Isfahan, Iran,
work phone:

Subspecialty, Fellowship in Cardiology, Tehran and Isfahan Universities of Medical Sciences, Iran.

Specialty in Internal Medicine. Isfahan University of Medical Sciences, Iran.

M.D Degree, Isfahan University of Medical Sciences.

Affiliate Professor, School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Visiting Professor, School of Population and Public Health & Cardiology Division Hospitals, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Visiting Professor, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Full Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Clinical Associate Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Clinical Assistant Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Outstanding Research Award of the Year, the Ministry of Health and Medical Education.

Outstanding Research Award of the Year, Isfahan University of Medical Sciences.

Outstanding Assistant Prof. of the Year Award, Isfahan University of Medical Sciences.

Has been selected for Who’s Who in America.

Special Presidential Award, by the Board of Directors of the International College of Nutrition.

Outstanding Woman Award of the Year, the Governor of Isfahan.

Outstanding Researcher of the Year 2001 Award, Isfahan University of Medical Sciences and Health Treatment Services in Isfahan.

Iranian Presidential Award for the Year’s National Razi Research Festival.

Outstanding Physician of the Year- Social Security Assurance Service Award, Iran.

Outstanding Physician of the Year- I.R of IRAN Medical Council Award.Isfahan,Iran

Merit & Worth Medal from International Research Academy of Cardiovascular Sciences, Winnepig, Canada.

Merit & Worth Medal from Eastern Mediterranean Region Atherosclerosis Association, Cairo, Egypt.

Outstanding Women of the Year 2003 in Isfahan, Iran.

Presidential Award, the National Research Razi Festival in Clinical Sciences.

Provincial Outstanding Researcher Award, Isfahan, Iran.

Presidential Medal of Honor (in the field of Merit & Management), Tehran, Iran.

Provincial Outstanding Award, Governor General of Isfahan, Iran.

Isfahan University of Medical Sciences, Research Chair Award, Isfahan, Iran.

Distinctive Researcher of the Country, the Ministry of Science and Technology, National Research Festival.

Governess General for Research Award

Elected Citizen Award, Municipality of Isfahan, Isfahan, Iran.

Selected as the Top Face of the Province, Isfahan, Iran

Presidential Award, the National Research Razi Festival, Health Promotion Committee, Tehran, Iran

Iranian Academy of Medical Sciences Award,Tehran, Iran

Governor General for Environment Protection Award,Tehran, Iran

Iranian Academy of Medical Sciences Award, Dr. Hadavi Award, Tehran, Iran

Outstanding Research Award of the Year, Isfahan University of Medical Sciences, Isfahan, Iran

Selected Author of the book of the year, Office of Culture and Islamic Guidance, Isfahan, Iran

Top Researcher of Isfahan University of Medical Sciences in the Fields of Having Most Papers and Highest Citations, Isfahan, Iran

Outstanding Research Award of the Year 2014 for Ranking the Highest International Collaborations and Grants Obtained from Internal and International Sources, Isfahan, Iran

Books or Chapters in Books:
1. Hennekers CH. H, Buring J.E. Epidemiology in Medicine (Translation), 1998.
2. Maghsoodloo. S. Cardiac Rehabilitation .Teimoorzadeh Publisher . (supervision) 2001.
3. Burgarella F. The HEARTBook. (translated), 2001.
4. Sarrafzadegan N, Sajadi F. Hypertension and diabetes prevalence, awareness, treatment and control in the Eastern Mediterranean Region: with special reference to Iran. Frontiers Cardiovascular Health. Edited by N.S.Dhalla, A. Chokalingam, H I Berkowitz & P.K.Singal. Kluwar Academic Publishers, Boston, 2003.
5. Sarrafzadegan N, et al. Effective strategies and actions for control and prevention of non-communicable diseases in Iran “Isfahan Healthy Heart Program”. (First IHHP Series Book), ) Isfahan University of Medical Sciences Publisher ,Isfahan , 2007.
6. Sarrafzadegan N, Alikhassi H. Isfahan Healthy Heart Program from design to implementation (Second IHHP Series Book) ) ,Isfahan University of Medical Sciences Publisher ,Isfahan, 2008.
7. Global Recommendations on Physical Activity for Health, World Health Organization, 2010 (peer reviewer)
8. Sarrafzadegan N. Educational Package of Isfahan Healthy Heart Program(3rd IHHP Series Book) Isfahan University of Medical Sciences Publisher ,Isfahan, 2011
9. Sarrafzadegan N, Rabiei K. Participation Compliance and Outcomes of Outpatient Cardiac Rehabilitation Programs Among Women in Low Resource Settings. Cardiac Rehabilitation, Nova Publisher Inc ,US, 2010; Chapter 8:185-199
10. Planning, Implementation and Evaluation of Non-Communicable Diseases Prevention and Control. WHO Publisher, 2010.

Published Articles In Peer-Reviewed Journals

International

1. Sarrafzadegan N, Adib M. Are the HLA antigens different in cardiac patients and healthy people? Iranian Journal of Medical Science 1995; 20(3&4):26-29.
2. Sarrafzadegan N, Amininik S. Blood pressure pattern in urban and rural area: Isfahan Hypertension Study. Journal of Human Hypertension 1997; 11(7): 424-28.
3. Sarrafzadegan N. Heart rate: a predictor of early mortality in patients with myocardial infarction. Iranian Journal of Medical Sciences 1997; 11(4): 295-8.
4. Boshtam M, Rafiei M, Sarrafzadegan N. Obesity and associated cardiovascular risk factors in Isfahan population: Isfahan Cardiovascular Risk Factor Survey. Atheroscleroza 1997; 1(4):7-11.
5. Asgary S, Sarrafzadegan N, Ghassemi N, Ghanadi A, Sajadi E, Sajadi F, Naderi Gh. Antihyperlipidemic effects of Crataegus Curvisepala lind. Intercontinental Cardiology 1998; 7(2): 73-75.
6. Nematbakhsh M, Rajabi P, Soltani SH, Sarrafzadegan N, et al. Estrogen attenuates endothelial permeability and fatty streaks in cholesterol- fed male rabbit aorta. Atheroscleroza 1998; 2(1): 3-7.
7. Rafiei M, Boshtam M, Sarrafzadegan N. Comparison of knowledge, attitude and practice of Isfahan population regarding the role of nutrition on coronary artery disease. Intercontinental Cardiology 1998; 7(1): 13-16.
8. Sarrafzadegan N, Alikhasi H, Abdar N. “Cardiovascular disease situation and preventive actions in Iran”. Atherosclerosis 1998; 136, Supplement 1: S53-S53.
9. Sarrafzadegan N, Sajadi F, Mohammadifard F. “Antihyperlipidemic effect of crataegus Curvisepala Lind”. Atherosclerosis 1998; 136, Supplement 1: S35-S35.
10. Mohammadifard N, Sarrafzadegan N, Jalali A, Rafiei M, et al. Food and nutrients intake among adults of Isfahan. South Asian J of Preventive Cardiology 1998; 2: 59-64.
11. Sarrafzadegan N, Boshtam M, Rafiei M. Risk factors for coronary heart disease in Isfahan. Europe J of Pub Health 1999; 9(1): 20-26.
12. Sarrafzadegan N, Sayed-Tabatabaei FA, Bashardoost N et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiologica 1999; 54(5): 257-263.
13. Sarrafzadegan N, Boshtam M, Malekafzali H, et al. Secular trends of mortality from cardiovascular disease in Iran: with special reference to Isfahan. Acta Cardiologica 1999; 54(6): 327-333.
14. Sarrafzadegan N, Boshtam M, Najafian J, Poorshams A, Samarian S. “Hypertension and dyslipidemia among Iranian people”. Atherosclerosis 1999;144, Supplement 1: S150-S151.
15. Sarrafzadegan N, Malekafzali H, Tabatabaei F, Tafazoli F, Boshtam M. “Cardiovascular disease in Iranian women, trends in incidence and mortality from CHD 1990-1996 in Isfahan”. Atherosclerosis 1999;144, Supplement 1: S187-S188.
16. Sarrafzadegan N, Mohammadifard N, Sajjadi F, Abdar N. “Abdominal obesity and lipoprotein disturbances among Iranians”. Atherosclerosis 1999;144,: Supplement 1:S 156-S156.
17. Sarrafzadegan N, Naderi GH, Asgary S, Zarie M, Samarian H. “Hemostatic factors, apolipoproteins and lipoprotein(a) levels among Iranians”. Atherosclerosis 1999;144, Supplement 1: S106-S107.
18. Sarrafzadegan N, Zarei M, Naderi GH, Asgari S, Samarian H, Karimi A, Fatehi-far R. “The effect of fasting during the month of holy Ramadan on apolipoprdeins and coagulation system”. Atherosclerosis 1999;144, Supplement 1 S174-S174.
19. Sarrafzadegan N, Zarei M, Samarian H, Naderi GH, Asgary S, Fatehi-far R. “The relation between apolipoproteins, lipoprotein(a) and hemostatic factors”. Atherosclerosis 1999;144 Supplement 1,: S106-S106.
20. Sarrafzadegan N, Jalali A, Alikhasi H, Samarian H, Mohammadifard N, Sajjadi F, Boshtam M. “Central obesity, nutritional status and lipid disturbances in Iranian women”. Atherosclerosis 1999;144, Supplement 1: S174-S174.
21. Sarrafzadegan N, Kelishadi R, Hashmipoor H, Samarian H, Naderi Gh, Asgari S. “Lipoprotein and apoprotein levels among Iranian high risk children”.Atherosclerosis 1999;144, Supplement 1:S 136-S136.
22. Asgary S, Naderi Gh, Sarrafzadegan N, Haeri MR, Boshtam B, Zarei M. “The free radical inhibitory effect of some flavonoids”. Atherosclerosis 1999;144 Supplement 1,: S188-S188.
23. Boshtam M, Rafiei M, Sarrafzadegan N, Asgary S, Khalili S, Zarfeshani S. “Smoking prevalence and its relation with some cardiovascular risk factors”. Atherosclerosis 1999;144, Supplement 1: S188-S189.
24. Mohammadifard N, Sarrafzadegan N, Sajadi F, Abdar N. “Body fat distribution, serum lipids, blood pressure and coronary artery disease in adults of Isfahan, Iran”. Atherosclerosis 1999;144 Supplement 1,:S 159-S159.
25. Sarrafzadegan N, Boshtam M, Mostafavi S, Rafiei M. “The prevalence of hypertension and associated risk factors in Isfahan”. Eastern Mediterranean Health J 1999; 5(5): 992-1001.
26. Asgary S, Sarrafzadegan N, Naderi Gh, et al. “Anti-oxidant effect of Flavonoids on hemoglobin glycosylation”. Pharmaceutica Acta Helvetica 1999; 73: 223-26.
27. Rafiei M, Boshtam M, Sarrafzadegan N. “Lipid profiles in the Isfahan population: Isfahan Cardiovascular Risk Factors Survey”. Eastern Mediterranean Health Journal 1999; 5(4):766-776.
28. Boshtam M, Sarrafzadegan N, Rafiei M, et al. “The relation between CK-MB/CK activity index and serum magnesium and fibrinogen in myocardial infarction”. Pakistan J Cardiol 1999; 10(2-3): 47-53.
29. Sarrafzadegan N, Atashi M, Naderi Gh, Baghai AM, et al. “The effect of fasting in Ramadan on the values and interrelations between biochemical, coagulation and hematological factors”. Annals of Saudi Medicine 2000; 20(5-6): 377-381.
30. Sarrafzadegan N, Singh RB, Rakesh Sharma, et al. “The Asian ethnic paradox: differences in dietary fat intake and risk of coronary artery disease in Iranian and Indian young – elderly populations”. J of Nutr and Environ Med 2000; 11: 113-119.
31. Asgary S, Nadery GH, Sarrafzadegan N, et al. “Antihypertensive and antihyperlipidemic effects of Achillea Wilhelmsii”. Drugs Under Experimental & Clinical Research 2000;26(3): 89-94.
32. Boshtam M, Rafiei M, Sarrafzadegan N, Asgary S. “Smoking prevalence and its combination with cardiovascular risk factors”. Acta Medica Iranica 2000; 38(2): 115-20.
33. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, Babilonia NA, Rahman ARA, Sheikh S, Tomlinson B, and Sarrafzadegan N. “Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention”. J of Human Hypertension 2000; 14:749-763.
34. Pourshams A, Mohammadifard N, Asgary S, Golshadi I, Sarrafzadegan N. “Evaluation of the international ‘Quit and Win’ contest 1998 in Isfahan”. Iran Arc Irn Med 2000; 3(2):75-77.
35. Boshtam M, Sadeghi K, Sarrafzadegan N, et al. “The effect of supervised exercise training on type of psychological characteristics and physical fitness after myocardial infarction”. Acta Medica Iranica 2000; 38(4):224- 228.
36. Sarrafzadegan N, Amiri M, Magsoodloo S. “The relation between Helicobacter Pylori & acute myocardial infarction”. Coronary Health Care 2001; 5: 1-6.
37. Kelishadi R, Hashemipour M, Sarrafzadegan N, et al. “Trend of atherosclerosis risk factors in children of Isfahan”. Asian Cardiovascular Thorac Ann 2001; 9: (36-40).
38. Garak Yaraghi M, Kianjoo M, Mortazavi M, Sarraf Zadegan N, Shemirani H, Shah Parian M. “Efficacy of GIKM (Glucose, Insulin, Potassium and Magnesium) therapy in the management of myocardial infarction compared to current thrombolytic therapy: A double blind randomized clinical trial”. J Res Med Sci. 2001;6(3):233-228.
39. Tavassoli AA, Behrad-Manesh S, Dehgan H, Sarrafzadegan N, et al. “Assessment of cost effectiveness of several strategies of early diagnosis in patients with acute chest pain & non conclusive electrocardiogram: The Iranian experience”. Journal of Molecular & Cellular & Cardiology 2008; 33(6):A121-A121.
40. Boshtam M, Rafiei M, Sadeghi M, Sarrafzadegan N. Vitamin E can reduce blood pressure in mild hypertensive. Int J vit Nut Res 2002; 72(5): 309-14.
41. Kelishadi R, Sarrafzadegan N, Nadery Gh, et al. Atherosclerosis risk factors in children & adolescents with or without family history of premature coronary heart disease. Medical Sciences Monit 2002; 8(6): 425-9.
42. Boshtam M, Sarrafzadegan N, Kelishadi R. “Relation of Serum Lipids, apolipoproteins & vitamin D of serum in children with high risk families regarding CVD & their comprehensive to the control group”. J Res Med Sci(JRMS) 2002; 7(2):122-127.
43. Naderi Gh, Asgary S, Ani M, Sarrafzadegan N, et al. Study on the effect of some pure plant volatile oils on the affinity of native & oxidized LDL and LDL oxide to its receptor in adrenal cell’s surfaces: J Medicinal Plants Research 2002; 1(1): 11-18.
44. Asgary S, Naderi Gh, Sarrafzadegan N, et al. Inhibitory effect of pure flavonoid on invitro protein glycosylation. J Herbal Pharmacotherapy 2002; 2(2):47-55.
45. Sarrafzadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S, Tolooie H, Poormoghaddas M, Sadeghi M, Tavassoli A, Rafiei M, Kelishadi R, Rabiei K, Bashardoost N, Boshtam M, Asgary S, Naderi G, Changiz T, Yousefie A. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol 2003 Aug;58(4):309-20.
46. Naderi Gh, Asgary S, Sarrafzadegan N, Shirvany H. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Molecular and Cellular Biochemistry 2003; 246: 193-196.
47. Asgary S, Naderi Gh, Sarrafzadegan N, Gharypour M. In vitro effect of nicotine and cotinine on the susceptibility of LDL oxidation and hemoglobin glycosylation. Molecular and Cellular Biochemistry 2003; 246: 117-120.
48. Fard NM, Sarrafzadegan N, Sajadi F, Rafiei M, Abdar. Effect of cardiac rehabilitation on lipid profile. J Assoc Physicians India 2003; 5:5-12.
49. Kelishadi R, Hashemipoor M, Sarrafzadegan N, et al. Obesity & associated modifiable environmental factors in Iranian adolescents: Isfahan Healthy Heart Program-Heart Health Promotion from Childhood. Pediatrics International 2003; 45(4):435-442.
50. Sarraf-Zadegan N. “Factor analysis of the metabolic syndrome among Iranian smokers and non-smokers”. Atherosclerosis Supplements 2003;4(2): 47-47.
51. Khosravi A, Kelishadi R, Sarraf-Zadegan N, Ansari R. “Trends in blood pressure level, prevalence of hypertension and its care in Isfahan, Iran (1991-2001)”. Atherosclerosis Supplements 2003;4(2): 39-3.
52. Khami MA, Sarraf-Zadegan N, Boshtam M, Bashardoost N, Malekafzali H, Tafazoli F. “Cardiovascular disease in Iran: Mortality, prevalence and risk factors over 15 years”. Atherosclerosis Supplements 2003;4(2): 112-112.
53. Fard NM, Mehrabian F, Sarrafzadegan N, Sajadi F. “Fat modified diets during pregnancy & lactation & serum lipids after birth. Indian J Pediatr 2004; 71(8):683-7.
54. Sarrafzadegan N, Boshtam M, Shahrokhi Sh, et al. “Tobacco use among Iranian women & adolescents”. European J of Public Health 2004; 14(1):76-85.
55. Kelishadi R, Sarrafzadegan N, Hashemipoor M et al. “Dietary fat intake and serum lipid profiles of Iranian adolescents: IHHP-HHPC”. Prev Med 2004; 39:760-766.
56. Kelishadi R, Sarrafzadegan N, Sadri GH et al. “Smoking, adolescents & health. Isfahan Health Heart Program- Heart Health Promotion from childhood”. Asian Pacific Journal of Public Health 2004; 16(1):15-22.
57. Nasidze I, Ling EYS, Quinque D, Dupanloup I, Cordaux R, Rychkov S, Naumova O, Zhukova O, Sarrafzadegan N, et al. “Mitochondrial DNA and Y-Chromosome variation in the Caucasus”. Annals of Human Genetics 2004; 68(3):205-221
58. Naderi Gh, Asgary S, Ani M, Sarrafzadegan N, et al. “Effect of some volatile oils on the affinity of intact and oxidized low-density lipoproteins for adrenal cell surface receptors”. Mol Cell Biochem 2004; 267:59-66.
59. Naderi Gh, Asgary S, Sarrafzadegan N, et al. “Antioxidant activity of three extract of Nigra”. Phytotherapy Research 2004; 18(5):365-369.
60. Pourmoghaddas M, Khosravi A, Kelishadi R, Sarrafzadegan N, Shirani Sh, Ansari R, Sabet B. “Trends in blood pressure level, prevalence and control of hypertension in Isfahan, Iran”. Iranian Heart Journal 2004; 5(1,2):33-38.
61. Boshtam M, Sarrafzadegan N, Rafiei M, Tafazoli F. Smoking habits among an Iranian population. Pakistan Journal of Cardiology 2005; 16(1):23-28.
62. Kelishadi R, Derakhshan R, Sabet B, Sarrafzadegan N, et al. The metabolic syndrome in hypertensive & normotensive subjects: The Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2005; 34(3):243-9.
63. Najafian J, Kelishadi R, Sarrafzadegan N, et al. “Mean duration of EKG changes in patients with unstable angina”. ARYA Atherosclerosis Journal, 2005; 1(2):85-88.
64. Sabet B, Derakhshan R, Sadeghi M, Sarrafzadegan N, et al. “Two -year incidence of acute fatal and non fatal Coronary events and stroke: Iranian Population over 35 Years old”. ARYA Atherosclerosis Journal, 2005; 1(1):9-14.
65. Baghaie AM, Gharipour M, Mohammadifard N, Sarrafzadegan N. “Secondary Prevention in cardiovascular disease: Closing the gaps”. ARYA Atherosclerosis Journal, 2005; 1(2):65-67.
66. Gharipour M, Baghaie AM, Rabiei K, Sarrafzadegan N. “Pharamacological treatment, lifestyle modification and awareness in coronary artery and cerebrovascular disease patients”. ARYA Atherosclerosis Journal, 2006; 1(4):261-265.
67. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. “Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel”. J Intern Med. 2006; 259(3):247-58.
68. Oveisgharan SH, Shirani SH, Baghaiei AM, Hosseini SH, Sarrafzadegan N. Barthel Index in a Middle East Country: Translation, validity & reability. Cerebrovascular Disease Journal. Cerebrovasc Dis 2006; 22:350-354.
69. Sarrafzadegan N, Baghaei AM, Sadri GH, Kelishadi R, Malekafzali H, Boshtam M, Amani A, Rabie K, Moatarian A, Rezaeiashtiani A, Paradis G, O’loghlin J. “Isfahan Healthy Heart Program: Evaluation of comprehensive, community-based interventions for non-communicable disease”. Prevention and Control J 2006; 2(2): 73-84.
70. Adibi P, Sadeghi M, Minakari M, Garak Yarayhi M, Rozati G, Sarrafzadegan N. “Hypertransaminasemia as a risk factor for coronary heart disease: a case–control study”. Journal of Gastroentrology and Hepatology. 2006; 21:A59-A59.
71. Sarrafzadegan N, Rabiei K, Shirani SH, Kabir A, et al. Drop-out predictors in cardiac rehabilitation programmes and the impact of sex differences among coronary heart disease patients in an Iranian sample: a cohort study. Clinical Rehabilitation 2007; 21(4):362-72.
72. Sniderman AD, Bohpal R, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity & its atherogenic consequences? The adipose tissue overflow hypothesis. International Journal of Epidemiology 2007; 36:220-225.
73. Daar A.S, Singer P.A, Persad D.L, Pramming S.K, Matthews D.R, Beaglehole R, Bernstein A, Borysiewicz L.K, Colagiuri S, Ganguly N, Glass R.I, Finegood D.T, Koplan J, Nabel E.G, Sarna G, Sarrafzadegan N, Smith R, Yach D and Bell J. Grand challenges in chronic non-communicable disease. Nature 2007; 450:494-496.
74. Oveisgharan Sh, Sarrafzadegan N, Shirani Sh, Khosravi AR, Hosseini Sh. Stroke in Isfahan, Iran: Hospital admission an 28-day case fatality rate. Cerebrorasc Dis 2007; 24:495-499.
75. Nucifora G, Budano LP, Sarrafzadegan N, et al. “Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain”. Am J Cardiol 2007; 100(7):1068-1073.
76. Shety P. “Sarrafzadegan N: Leading Cardiovascular Research in Iran”. Lancet 2007; 18:370(9587):559.
77. Liu W, Garipour M, Asgary S, Sadeghi M, Davis N, Sarrafzadegan N, Mani A. “Lrp6 Mediates Cellular Cholesterol Uptake”. Circulation 2007; 116:II-183.
78. Sarrafzadegan N, Rabiei K, Kabir A, et al. Changes in lipid profile of patients referred to a cardiac rehabilitation program. European Journal of Cardiovascular Prevention & Rehabilitation 2007; 15(4):467-472.
79. Sadeghi M, Roohafza H, Shirani Sh, Poormoghadas M, Kelishadi R, Baghaiei AM, Sarrafzadegan N. Diabetes and associated cardiovascular risk factors in Iran: The Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2007; 36:175-80.
80. Roohafza H, Sadeghi M, Sarrafzadegan N, et al. Short communication: Relation between stress and other life style factors. Stress and Health 2007; 23(1):23-29.
81. Abdi A, Khosravi A, Sarrafzadegan N, et al. “The effect of low-dose Niacin added to Simvastation on lipoprotein profile”. ARYA Atherosclerosis Journal, 2007; 3(1):8-13.
82. Javid Hussain Akhtar, Sarrafzadegan N, Mohammadifard N, et al. “Is there any difference between dietary habits in hypertensive, hyperlipidemics, obese, smoker, individuals and the normal population?”. ARYA Atherosclerosis Journal, 2008; 4(3):112-120.
83. Nazari N, Asgary S, Sarrafzadegan N, et al. “Content of long chain omega-3 fatty acid composition in some Iranian canned fish”. ARYA Atherosclerosis Journal, 2008; 4(3): 93-97.
84. Sarrafzadegan N, Rezapurian P, Kaypour M, Mohseni M, Sadeghi M, Asgary S & Sabet B. “Prognostic value of infection & inflammation markers for late cardiac events in an Iranian sample”. Eastern Mediterranean Health Journal 2008; 14(6):1246-1256.
85. Sadeghi M, Sadat Razavi N, Sarrafzadegan N, et al. Early & late effect of high dose Atorvastatin and low dose Atorvastatin on serum C-Reactive protein reduction in non-ST elevation myocardial infarction. ARYA Atherosclerosis Journal, 2008; 4(1): 6-12.
86. Sarrafzadegan N, Rabiei K, Kabir A, et al. “Gender differences in risk factors and outcomes after cardiac rehabilitation”. Acta Cardiol 2008; 63(6): 763-770.
87. Liu W, Mani S, Davis NR, Sarrafzadegan N, KAvatha PB, Mani A. Mutation in EGFP Domain of LDL Receptor-related protein 6 imysairs cellular LDL clearance. Circulation Research 2008; 103(1):1280-8.
88. Shahrokhi Sh. Kelishadi R, Sarrafzadegan N, et al. “Evaluation of the Quit & Win contest for smoking cessation in the Islamic republic of Iran”. Eastern Mediterranean Health Journal 2008; 14(6):1270-1279.
89. Asgary S, Sarrafzadegan N, Naderi Gh, et al. “Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and rote of administration matter”. Lipid & Health and Disease 2008; 7:42.
90. Rafiei M, Boshtam M, Sarrafzadegan N, et al. “The relation between salt intake and blood pressure among Iranians”. Kuwait Medical Journal 2008; 40(3):191-195.
91. Sarrafzadegan N, Kelishadi R, Baghaiei AM, et al. “Metabolic syndrome: An emerging public health problem in Iranian women: Isfahan Healthy Heart Program”. International Journal of Cardiology 2008; 131(1):90-96.
92. Gharipour M, Kelishadi R, Sarrafzadegan N, et al. “The association of smoking and components of the Metabolic Syndrome in Non-diabetic Patients”. Ann Acad Med Singapore 2008; 37(11):919-923.
93. Grandi S, Gervais A, Joseph L, O’Loughlin J, Paradis G, Pilote L, Rinfret S, Sarrafzadegan N, et al. “Smoking cessation following coronary syndrome”. Journal of Americal College of Cardiology 2008; 51(10):A368-A368 Suppl A MAR 11.
94. Sarrafzadegan N, Sadeghi M, Tavassoli AA, et al. “Sex-difference in the impact of a community-based program for non-communicable disease prevention: The Isfahan Healthy Heart Programme (IHHP)”. Journal of Public Health 2009; 17:257-263.
95. Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, et al. “Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in Iran”. Bulletin of World Health Organization 2009; 87:39-50.
96. Rabiei K, Kelishadi R, Sarrafzadegan N, et al. “Process evaluation of a community-based program for prevention and control of communicable disease in a developing country: The Isfahan Healthy Heart Program”. BMC Public Health 2009; 9:57.
97. Mohammadifard N, Kelishadi R, Safavi M, Sarrafzadegan N, et al. “Effect of a community-based intervention on nutritional behavior in a developing country setting: the Isfahan Healthy Heart Program. Public Health Nutr 2009; 17:1-9.
98. Tabib A, Siadat Z, Sarrafzadegan N, Klishadi R, Zarfeshani S, Khosravi A. “Smoking and lipids”. Atherosclerosis Supplements 2009; 10(2):e1062-e1062.
99. Asgary S, Nazari B, Sarrafzadegan N, Saberi S, Azadbakht L, Esmaillzadeh A. “Trans fatty acid content of some Iranian commercial food prodocts”. Atherosclerosis Supplements 2009; 10(2): e759-e759.
100. Gharipour M, Sarrafzadegan N, Siadat S, Maghroun M, Abdolvand A. “Metabolic Syndrome epidemiology based on socioeconomic statuse: Cross sectional study among Iranian adult population”. Atherosclerosis Supplements 2009; 10(2): e1352-e1352.
101. Nucifera G, Badano LP, Sarrafzadegan N, et al. “Effect on quality of life of different accelerated diagnostic protocols for management of patients presenting to the emergency department with acute chest pain”. Am J Cardiol 2009; 103(5):592-7.
102. Sarrafzadegan N, Ashrafi F, Noorbakhsh M, et al. “The Association of breast artery calcification with coronary artery disease & carotid Intima-media thickness in Iranian pre-menopausal women”. Easter Mediterranean Health J 2009; 15(6): 1474-1482.
103. Roohafza H, Sadeghi M, Shirani S, Bahonar A, Mackie M, Sarrafzadegan N. “Association of socioeconomic status and lifestyle factors with stress coping strategic in Isfahan Healthy Heart Program”. Croat Med J 2009; 50(4):380-6.
104. Sarrafzadegan N, Azadbakht L, Mohammadifar N et al. “Do lifestyle interventions affect dietary diversity score in the general population?” Public Health Nutrition 2009; 12(10):1924-1930.
105. Asgary S, Nazari B, Sarrafzadegan N, et al. “Evaluation of fatty acid content of some Iranian fast foods with emphasis on trans fatty acids”. Asia Pac J Clin Nutr. 2009; 18(2): 187-92.
106. Solhpour AR, Parkhideh S, Sarrafzadegan N, Asgary S, et al. “Levels of Lipids and Apolipoproteins in Three Cultres”. Atherosclerosis. 2009;207(1):200-7
107. Shirani S, Kelishadi R, Sarrafzadegan N, Khosravi A, Sadri GH, et al. Awareness, treatment and control of hypertension, dyslipidemia and diabetes mellitus in an Iranian population: Isfahan Healthy Heart Program. Easter Mediterranean Health J. 2009; 15(6):1455-1463.
108. Hashemipour M, Kelishadi R, Shapouri J, Sarrafzadegan N, et al. “Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children”. Hormones 2009; 8(4):279-285.
109. Maghzi AH, Etemadifar M, Ramezani MA, Sarrafzadegan N, et al. “Does Ramadan fasting influence the incidence & short-term survival of stroke?”. Journal of Neurology 2009; 256:S172-S172.
110. Mosavi E, Gharipour M, Tavassoli A, Sadri GH, Sarrafzadegan N. “Multiparity and risk of metabolic syndrome: Isfahan Healthy Heart Program”. Metab Syndr Relat Disord 2009; 7(6): 519-24.
111. Khosravi A, Avesta L, Kelishadi R, Ramezani M, Bahonar A, Heydari H, Tavassoli A, Sarrafzadegan N. Assessment of relation between microalbuminuria and ischemic electrocardiogram in Iranian general population. ARYA Atherosclerosis Journal 2009;5(1):27-32.
112. Asgari S, Nazari B, Sarrafzadegan N, et al. “Fatty acid composition of commercially available Iranian edible oils”. J Res Med Sci. 2009; 14(4):211-215.
113. Bahonar A, Khosravi A, Esmaeelian H, Babak A, Rahmati M, Jamshidi A, Azad M, Daneshvar P, Sarrafzadegan N. Methods of implementing the operational phases of the health professionals education project Isfahan Healthy Heart Program (IHHP-HPEP). ARYA Atherosclerosis Journal, 2009;5(3):103-107.
114. Roohafza H, Sarrafzadegan N, Shahnam M, et al. Are community-based intervention programs effective in the youth population? Results from Isfahan Healthy Heart Program. ARYA Atherosclerosis Journal, 2009;5(3):111-117.
115. Sarrafzadegan N, Oveisgharan Sh, Toghianifar N, et al. Acute myocardial infarction in Isfahan, Iran: Hospitalization & 28th day case-fatality rate. ARYA Atherosclerosis Journal, 2009;5(3):132-137.
116. Sadeghi M, Tavasoli A, Roohafza H, Sarrafzadegan N. “The relationship between ankle-brachial index and number of involved coronaries in patients with stable angina”. ARYA Atheroscler 2010; 6(1):6-10.
117. Sarrafzadegan N, Kelishadi R, Najafian A, et al. “Anthropometric Indices in Association with Cardiometabolic Risk Factors: Findings of the Isfahan Healthy Heart Program. ARYA Atherosclerosis Journal, 2010; 5(4):152-162.
118. Mozafari M, Sadeghi M, Sanei H, Ramezani MA, Golabchi A, Sarrafzadegan N. “Evaluation of leptin and adiponectin levels in patients with stable angina pectoris”. ARYA Atherosclerosis Journal, 2010; 6(2):50-55.
119. Baghaei A, Sarrafzadegan N, Rabiei K, et al. How effective are strategies for non-communicable disease prevention & control on high risk population in a developing country Isfahan Healthy Program. Archives of Medical Sciences 2010; 6(1):24-31.
120. Golabchi A, Sarrafzadegan N. “What every cardiologist should know about H1N1?” ARYA Atherosclerosis Journal, 2010; 6(3):117-120.
121. Hajmohammadi T, Sadeghi M, Dashti M, Hashemi M, Saadatnia M, Soghrati M, Talaei M, Sarrafzadegan N. “Relationship between carotid intima-media thickness with some inflammatory biomarkers, ghrelin and adiponectin in Iranians with and without metabolic syndrome in Isfahan cohort study”. ARYA Atherosclerosis Journal, 2010; 6(2):56-61.
122. Rabiei K, Kelishadi R, Sarrafzadegan N, Sadri Gh, et al. “Short-term results of community-based interventions for improving physical activity: Isfahan Healthy Heart Program”. Archives of Medical Sciences 2010; 6(1):32-39.
123. Shahnam M, Roohafza H, Sadeghi M, Tavassoli A, Bahonar A, Sarrafzadegan N. “The correlation between lipid profile and stress levels in part central Iran: Isfahan healthy heart program”. ARYA Atherosclerosis Journal, 2010; 6(3):101-104.
124. Sarrafzadegan N, Kelishadi R, Siadat ZD, Esmaillzadeh A, Solhpour A, Shirani Sh, et al. “Obesity and Cardiometabolic Risk Factors in a representative population of Iranian adolescents and adults in comparison to western population: IHHP”. Public Health Nutrition 2010; 13(3):314-323.
125. Cheraghi M, Sadeghi M, Sarrafzadegan N, Pourmoghadas A, Ramezani MA. “Prognostic factors for survival at 6-month follow-up of hospitalized patients with decompenstated congestive heart failure”. ARYA Atherosclerosis Journal, 2010; 6(3):11-116.
126. Sarrafzadegan N, Toghianifar N, Roohafza H, Siadat Z, Mohammadifard N, O’Loughlin J. “Lifestyle-related Determinants of Hookah and Cigarette Smoking In Iranian Adults”. J Community Health 2010; 35:36-42.
127. Yousefy AR, Ghassemi GR, Sarrafzadegan N, Mallik S, Baghaei AM, Rabiei K. “Psychometric properties of the WHOQOL-BREF in an Iranian adult sample”. Community Ment Health J. 2010;46(2):139-47.
128. Gharipour M, Kelishadi R, Toghyanifar N, Mackie M, Sarrafzadegan N, Noori F. “Pharmacological Treatment of Cardiovascular Risk Factors in Individuals with Metabolic Syndrome: Findings from the Isfahan Healthy Heart Program. Journal of Hypertension 2010; 28: e107.
129. Roohafza H, Talaei M, Sadeghi M, Mackie M, Sarrafzadegan N. “Association between Acute and Chronic Life Events on Acute Coronary Syndrome: A Case-Control Study”. J Cardiovasc Nurs. 2010;25(5):E1-E7.
130. Kelishadi R, Hashemipour M, Sarrafzadegan N, et al. “Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents”. Matern Child Nutr. 2010;6(3):275-86.
131. Bahonar A, Sarrafzadegan N, Kelishadi R, Shirani S, Ramezani MA, Taghdisi MH, Gharipour M. “Association of socioeconomic profiles with cardiovascular risk factors in Iran: the Isfahan Healthy Heart Program”. International Journal of Public Health. 2010; 56(1):37-44.
132. Tavassoli AA, Gharipour M, Khosravi A, Kelishadi R, Siadat ZD, Bahonar A, Sadri GhH, Sadeghi M, Rabiei K, Sajjadi F, Zarfeshani S, Eshrati B, Shirani Sh, Sarrafzadegan N. Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: The IHHP Study. J Health Popul Nutr. 2010; 28(6):602-609.
133. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadifard N, Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetology & Metabolic Syndrome 2010; 2:59.
134. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, Sajjadieh A R, Kabiri P, Marshall T, Thomas G N and Tavasoli A. “The Isfahan Cohort Study: Rationale, methods and main findings”. Journal of Human Hypertension 2010; 25(9):545-553.
135. Khosravi AR, Kiani Mehr G, Kelishadi R , Shirani S, Gharipour M, Tavassoli A, Noori F, Sarrafzadegan N. “The Impact of a 6-year Comprehensive Community Trial on the Awareness, Treatment and Control Rates of Hypertension in Iran: Experiences from the Isfahan Healthy Heart Program”. BMC Cardiovascular Disorders 2010; 10:61.
136. Nazari B, Asgary S, Sarrafzadegan N. “Warning about Fatty Acid Compositions in Some Iranian Mayonnaise Salad Dressings”. Int J Prev Med. 2010;1(2):110-4.
137. Sarrafzadegan N, Sadri G, Melek-Afzali M. “Effect of a 6-year comprehensive community-based program on cardiovascular risk factors: Experiences from demonstration study in a developing country”. Circulation 2010;122(2): E81-E81.
138. Sarrafzadegan N, Rabiei K, Zarfeshani S. “lessons learned from failures: Experiences of demonstration program for cardiovascular disease prevention and control”. Circulation 2010;122(2): E358-E358.
139. Bahonar A, Sarrafzadegan N, Kelishadi R, Ramezani MA, Gharipour M, Shirani S. “Relationship between socioeconomic profiles with cardiovascular risk factors in Iran: The IHHP Study”. Circulation 2010;122(2): E186-E186.
140. Gharipour M, Sarrafzadegan N, Toghianfar N, Mackie M, Noori F. Metabolic Syndrome: “Patient compliance with drug treatment (Isfahan Healthy Heart Study)”. Circulation 2010;122(2): E139-E139.
141. Toghianifar N, Sarrafzadegan N, Ramezani MA, Bahonar A, Nouri F. “Smoking cessation advice among hypertensive patients in a population-based sample of Iranian adults (IHHP)”. Circulation 2010;122(2): E277-E277.
142. Golabchi A, Sarrafzadegan N, Pormoghaddas M. “A woman with Typical Chest Pain and Broken Heart”. J Cardiovasc Thorac Res 2011; 2(4):31-34.
143. Kelishadi R, Sarrafzadegan N, Sadri GH, Pashmi R, Mohammadifard N, Tavasoli AA, Amani A, Rabiei K, Khosravi A, Bahonar A. “Short-term results of a community-based program on promoting healthy lifestyle for prevention and control of chronic diseases in a developing country setting: Isfahan Healthy Heart Program”. Asia Pac J Public Health. 2011;23(4):518-33.
144. Roohafza H, Sadeghi M, Shahnam M, BahonarA and Sarrafzadegan N. Perceived factors related to cigarette and waterpipe (ghelyan) initiation and maintenance in university students of Iran. Int J Public Health 2011; 56:175–180.
145. Roohafza H, Ramezani A Sadeghi M, Shahnam M, Zolfaghari B, Sarrafzadegan N. “Development and validation of the Stressful Life Event (SLE) questionnaire”. International Journal of Public Health, 2011; 56(4):441-8.
146. Sarrafzadegan N, Gharipour M, Tavassoli A, et al. “Metabolic syndrome and health-related quality of life in Iranian population”. 2011; 16(3):254-261.
147. Gharipour M, Kelishadi R, Toghianifar N, Mackie M, Yazdani M, Noori F, Sarrafzadegan N. “Sex based pharmacological treatment in patients with metabolic syndrome: Findings from the Isfahan healthy heart program”. African Journal of Pharmacy and Pharmacology 2011; 5(3):311-316.
148. Khosravi A, Pourmoqhadas M, Ostovan M, Kiani Mehr G, Gharipour M, Zakeri S, Soleimani B, Namdari M, Hassanzadeh M, Tavasolli AA, Ghaffari S, Khaledifar A, Roghani F, Khosravi MR, Sarami SH, Kojouri J, Nori F, Khosravi E, Jozan M and Sarrafzadegan N. “The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study”. 2011;16(5):640-50.
149. Samsamshariat S, Basati Gh, Movahedian A, Pourfarzam M, Sarrafzadegan N. “Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease”. 2011; 16(5):674-9.
150. Gharipour M, Kelishadi R, Toghianifar N, Tavassoli AA, Khosravi AR, Sajadi F, Sarrafzadegan N. “Socioeconomic disparities and smoking habits in metabolic syndrome: evidence from Isfahan Healthy Heart Program”. Iran Red Crescent Med J. 2011; 13(8):537-543.
151. Basati Gh, Pourfarzam M, Movahedian A, Samsamshariat S.Z, Sarrafzadegan N. “Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients”. CLINICAL SCIENCE, 2011; 66(7):1129-35.
152. Samsamshariat SZ, Basati Gh, Movahedian A, Pourfarzam M, Sarrafzadegan N. “Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease”. Biomarkers Med. 2011;5(3), 377–385.
153. Tavassoli A, Gharipour M, Toghianifard N, Sarrafzadegan N, et al. “The impact of obesity on hypertension and diabetes control following healthy lifestyle intervention program in a developing country setting”. 2011;16(Special Issue):368-376.
154. Golabchi A, Sarrafzadegan N. “Takotsubo cardiomyopathy or broken heart syndrome: A review article”. J Res Med Sci. 2011;16(3):340-5.
155. Kabir A, Sarrafzadegan N. “The real role of exercise versus medication in lipid profile of patients referred to a cardiac rehabilitation program”. Eur J Cardiovasc Prev Rehabil. 2011;18(4):680-1.
156. Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJ, Kayani AM, Abeysinghe N, Duneas A, Tabagari S, Fan W, Sarraf-Zadegan N, Nordet P, Whitworth J, Heagerty A. “Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings”. J Clin Epidemiol 2011;64(12):1451-62.
157. Toghianifar N, Sarrafzadegan N, Roohafza H, Sadeghi M, Eshrati B, Sadri G. “Smoking cessation support in Iran: availability, sources & predictors”. Indian J Med Res. 2011;133(6):627-32.
158. Sarrafzadegan N, Rabiei K, Alavi M, Abedi H and Zarfeshani S. “How can the results of a qualitative process evaluation be applied in management, improvement and modification of a preventive community trial? The IHHP Study”. Archives of Public Health 2011; 69:9.
159. Najafpour Boushehri S, Mohamad Yiusof R, NasirMohamad Taib I, Yassin Z, Sarrafzadegan N, et al. “Effects of antioxidant vitamins (C, E, Beta-Carotene) supplementation on serum 8-iso-prostaglandin PGF2a in male subjects with risk factors for cardiovascular diseases”. Middle-East Journal of Scientific Research 2011; 10(5):577-580.
160. Sadeghi M, Roohafza H, Afshar H, Rajabi F, Ramzani MA, Shemirani H, Sarrafzadegan N. “Relationship between depression and apolipoproteins A and B: a case–control study”. CLINICS 2011; 66(1):113-117.
161. Rajabizadeh G, Ramezani MA, Roohafza H, Pourdamghan N, Khosravi A, Rabiei K, Sarrafzadegan N, Toghianifar N, Zarfeshani S. “Association between cigarette smoking and socio-emographics, lifestyle and mental health factors in a sampled Iranian population”. Southeast Asian J Trop Med Public Health, 2011; 42(4):977-87.
162. Shirani Sh, Gharipour M, Khosravi A, Kelishadi R, Habibi H.R, Abdalvand A, Sarrafzadegan N. “Gender differences in the prevalence of hypertension in a representative sample of iranian population: The Isfahan Healthy Heart Program”. Acta Biomed 2011; 82: 223-229.
163. Toghianifar N, Najafian J, Pooya A, Rabiei K, Eshrati B, Anaraki J and Sarrafzadegan N. “Association of smoking status with quality of life in a cross-sectional population-based Sample of Iranian adults: Isfahan Healthy Heart Program”. Asia Pac J Public Health 2011; 24(5):786-94.
164. Sadeghi M, Aghdak P, Motamedi N, Tavassoli A, Kelishadi R, Sarrafzadegan N. “Do intervention strategies of women healthy heart project (WHHP) impact on differently on working and housewives?”. ARYA Atheroscler, 2011; 6(4):129-35.
165. Mohammadifard N, Sarrafzadegan N, Nouri F, Sajadi F, Alikhasi H, Maghroon M, Kelishadi R, Iraji F, Rahmati MR. “Using factor analysis to indentify dietary patterns in Iranian adults: Isfahan Healthy Heart Program”. International Journal of Public Health 2011; 57(1):235-241.
166. Akhlaghi A, Shirani Sh, ZiaieN, Pirhaji O, Yaran M, Shahverdi G, Sarrafzadegan N, Khosravi A, Khosravi E. “Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease”. ARYA Atherosclerosis Journal, 2011; 7(3):1-6.
167. Roohafza H, Shahnam M, Zolfaghari B, , Tavassoli A, Sadeghi M, Toloei HR, Sadri G, Sarrafzadegan N. “Stress level and smoking status in central Iran: Isfahan Healthy Heart Program”. ARYA Atherosclerosis Journal, 2011; 6(4): 144-148.
168. Sadeghi M, Pourmoghaddas Z, Alisaeidi A, Boshtam M, Yazdekhasti S, Sarrafzadegan N. “Is there any relation between Circulating Endothelial-Leukocyte adhesion molecule -1 and extent of coronary artery involvements in men with angina pectoris?”. Iranian Heart Journal 2011;12(4):37-42.
169. Mazaheri Sh, Sadeghi M, Sarrafzadegan N, Sanei H, Hekmatnia A, Tavakoli B. “Correlation between body fat distribution, plasma lipids and apolipoproteins with the severity of coronary involvement in patients with stable angina”. ARYA Atherosclerosis Journal, 2011; 6(4):142-146.
170. Sadri Gh, Sadeghi M, Sarrafzadegan N, Roohafza H, Yazdani H, Boshtam M, et al. “The relation between hematologic variables and metabolic syndrome”. Iranian Heart Journal 2011; 12(3):40-6.
171. Haghjoo S, Haghdoost F, Keyhanian K, Samety AA, Loghmani P, Rafiee L, Sarrafzadegan N, Asgari S. “Association between Heme Oxigenase-1 gene promoter polymorphisms and metabolic syndrome in Iranians”. Clinical Biochemistry 2011;44(13): S302-S303.
172. Basati G, Ziaaldin SS, Movahedian A, Pourfarzam M, Sarrafzadegan N. “The association of plasma leptin and homocysteine levels with the severity of coronary artery disease”. Clinical Biochemistry 2011;44(13): S1-S1.
173. Roohafza H, Sarrafzadegan N, Sadeghi S, Talaei M, Talakar M, Mahvash M. “The effectiveness of stress management intervention in a community-based program: Isfahan healthy heart program”. ARYA Atherosclerosis Journal, 2012; 7(4):176-183.
174. Sadeghi M, Sarrafzadegan N, Shahabi J, Naghnaiian M, Hedayat P. “The five-year trend of coronary artery diseases based on angiography results in central part of Iran”. Iranian Heart Journal, 2012; 13(2):12-19.
175. Talaei M, Sadeghi M, Marshall T, Thomas GN, Kabiri P, Hoseini S, Sarrafzadegan N. “Impact of metabolic syndrome on ischemic heart disease – A prospective cohort study in an Iranian adult population: Isfahan cohort study”. Nutr Metab Cardiovasc Dis. 2012; 22(5):434-41.
176. Sarrafzadegan N, Gharipour M, Sadeghi S, Khosravi A, Tavassoli AA. “Metabolic syndrome in Iranian elderly”. ARYA Atherosclerosis Journal, 2012; 7(4):157-161.
177. Javanmard SH, Keyhanian K, Loghmani P, Samety AA, Haghdoost F, Rafiei L, Talaei M, Asgari S, Jazi MH, Sarrafzadegan N. “Association between heme oxygenase-1 gene promoter polymorphisms and metabolic syndrome in Iranians”. Mol Biol Rep. 2012;39(3):3355-60.
178. Talaei M, Thomas GN, Marshall T, Sadeghi M, Iranipour R, Oveisgharan Sh, Sarrafzadegan N. “Appropriate cut-off values of waist circumference to predict cardiovascular outcomes: 7-year follow-up in an Iranian population”. Intern Med. 2012; 51(2):139-46.
179. Khosravi A, Toghianifar N, Sarrafzadegan N, Gharipour M, Azadbakht L. “Salt intake, obesity, and pre-hypertension among Iranian adults: A cross-sectional study”. Pakistan Journal of Medical Sciences 2012; 28(2):297-302.
180. Kabir A, Sarrafzadegan N, Amini A, Safi Aryan R, Habibi Kerahroodi F, Rabiei K, Taghipour HR, Moghimi M. “Impact of Cardiac Rehabilitation on Metabolic Syndrome in Iranian Patients with Coronary Heart Disease: The Role of Obesity”. Rehabilitation Nursing 2012; 37(2):66-73.
181. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, et al. “Different measurements of the obesity, adiponectin and coronary heart disease”. J Res Med Sci.2012; 17(4):1-4.
182. Sarrafzadegan N, Talaei M, Kelishadi R, Toghianifar N, Sadeghi M, Oveisgharan S, Kabiri P, Tavassoli A, Mohammadifard N, Thomas GN, Marshall T. “The influence of gender and place of residence on cardiovascular diseases and their risk factors. The Isfahan Cohort Study”. Saudi Med J. 2012; 33(5):533-40.
183. Roohafza H, Sadeghi M, Talaei M, Pourmoghaddas Z, Sarrafzadegan N. “Psychological Status and Quality of Life in relation to the Metabolic Syndrome: Isfahan Cohort Study”. International Journal of Endocrinology 2012. doi: 10.1155/2012/380902.
184. Masoudkabir F, Toghianifar N, Talaie M, Sadeghi M, Sarrafzadegan N, Mohammadifard N, Marshall T, Thomas G.N. “Socioeconomic status and incident cardiovascular disease in a developing country: findings from the Isfahan cohort study (ICS)”. Int J. Public Health 2012;57(3):561-8.
185. Sarrafzadegan N, Kelishadi R, Siavash M, Sadri Gh, Malekafzali H, Pourmoghaddash M, Shirani Sh, et al. “How Does the Impact of a Community Trial on Cardio-metabolic Risk Factors Differ In Terms of Gender and Living Area? Findings from the Isfahan Healthy Heart Program”. J Res Med Sci. 2012; 17(8):732-40.
186. Khosravi AR, Kelishadi R, Sarrafzadegan N, Boshtam M, Nouri Zarfeshani S. “Impact of a Comprehensive Healthy Lifestyle Program on Blood Pressure and Salt Intake in Normotensive Adults: the IHHP study”. J Res Med Sci. 2012; 17(3):235-241.
187. Sadeghi M, Golabchi A, Haghani P, Gharipour M, Naderi GA, Sarrafzadegan N. “Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?”. J Pak Med Assoc. 2012; 62(3) Suppl 1:S31-4.
188. Mohammadifard N, Fahimi S, Khosravi A, Pouraram H, Sajedinejad S, Pharoah P, Malekzadeh R, Sarrafzadegan N. “Advocacy strategies and action plans for reducing salt intake in iran”. Arch Iran Med. 2012; 15(5):320-4.
189. Khosravi-Boroujeni H, Sarrafzadegan N, Mohammadifard N, Alikhassi H, Sajjadi F, Asgari S, Esmaillzaded A. “Consumption of sugar-sweetened beverages in relation to the metabolic syndrome among Iranian adults”. Obes Facts 2012; 5(4):527-37.
190. Sarrafzadegan N, Sadeghi M, Khademi F, Ramezani MA, Hashemi Jazi M.“The relation of cardiovascular risk factors and Electrocardiogram (EKG) changes”. ARYA Atherosclerosis Journal 2012, 7(Suppl): S94-S98
191. Sarrafzadegan N, Sadeghi M, Ghaffarpasand F, Alisaeidi A, Sanei H, Zakeri H, Rastegar T, Amiri A, Dehghankhalili M. “Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris. A comparative study. Herz. 2012;37(8):926-30.
192. Khosravi A, Kelishadi R, Sarrafzadegan N, Boshtam M, Nouri F, Zarfeshani S, Esmaillzadeh A. “Impact of a community-based lifestyle intervention program on blood pressure and salt intake of normotensive adult population in a developing country”. J Res Med Sci. 2012; 17(3):235-41.
193. Sabzghabaee AM, Dianatkhah M, Sarrafzadegan N, Asgary S, Ghannadi A. “Clinical evaluation of Nigella sativa seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial”. Med Arh. 2012; 66(3):198-200.
194. Khosravi Boroujeni H, Mohammadifard N, Sarrafzadegan N, Sajjadi F, Maghroun M, Khosravi A, Alikhassi H, Azadbakht L. “Potato consumption and CVD risk factors among Iranian population”. International Journal of Food Sciences and Nutrition, 2012; 63(8):913-20.
195. Aghababaei I, Sadeghi M, Talaei M, Rabiei K, , Sarrafzadegan N. “Is prehypertension a risk factors for cardiovascular diseases among Iranian women?” J Res Med Sci. 2012; 17(10): 947–951.
196. Nezarat N, Sadeghi M, Rabiei K, Afsharmoghaddam N, Sarrafzadegan N, Setareh M, et al. “The Effect of body fat distribution on coronary and carotid atherosclerosis (An autopsy Study)”. J Res Med Sci 2012; 17(Spec 1):S125-S130.
197. Noohi F, Sarrafzadegan N, Khosravi A, Andalib E. “The first Iranian recommendations on prevention, evaluation and management of high blood pressure”. ARYA Atherosclerosis Journal, 2012; 8(3):9.
198. Ghashghaei FE, Sadeghi M, Rabiei K, Roohafza H, Sarrafzadegan N. “Gender differences in risk factors of obese patients after cardiac rehabilitation program”. Iran J Nurs Midwifery Res. 2012;17(5):381-5.
199. Kelishadi R, Mohammadifard N, Sarrafzadegan N, Nouri F, et. al. “The effects of a comprehensive community trial on cardiometabolic risk factors in adolescents: Isfahan Healthy Heart Program”. ARYA Atheroscler. 2012;7(4):184-90.
200. Aghababaei I, Sadeghi M, Talaei M, Rabiei K, Sarrafzadegan N. “Do hypertension and prehypertension count as cardiovascular risk factors among women in an Iranian society”. International Journal of Cardiology 2012 ;155, Supplement 1:S2-S2
201. Sarrafzadegan N, Kelishadi R, Siavash M, Sadri G, Malekafzali H, Pourmoghaddas M, Shirani S, Boshtam M, Asgary S, Mohammadifard N, Bahonar A, Eshrati B, Ghamsari F. “How does the impact of a community trial on cardio-metabolic risk factors differ in terms of gender and living area? Findings from the Isfahan healthy heart program”. J Res Med Sci. 2012;17(8):732-40.
202. Boshtam M, Ramezani MA, Naderi G, Sarrafzadegan N. “Is Fried Ewald formula a good estimation for low density lipoprotein level in Iranian population?”. J Res Med Sci. 2012; 17(6):519-22.
203. Ghashghaei FE, Sadeghi M, Mostafavi S, Heidari H, Sarrafzadegan N. “The effect of the cardiac rehabilitation program on obese and non-obese females with coronary heart disease”. Adv Biomed Res. 2012; 1:17. doi: 10.4103/2277-9175.96077.
204. Khosravi AR, Rowzati M, Gharipour M, Fesharaki MG, Shirani S, Shahrokhi S, Jozan M, Khosravi E, Khosravi Z, Sarrafzadegan N. “Hypertension control in industrial employees: findings from SHIMSCO study”. ARYA Atheroscler 2012; 7(4):191-6.
205. Khosravi-Boroujeni H, Mohammadifard N, Sarrafzadegan N, Sajjadi F, Maghroun M, Khosravi A, Alikhasi H, Rafieian M, Azadbakht L. “Potato consumption and cardiovascular disease risk factors among Iranian population”. Int J Food Sci Nutr. 2012; 63(8):913-20.
206. Abolhassani S, Irani MD, Sarrafzadegan N, Rabiei K, Shahrokhi S, Pourmoghaddas Z, Mohammadifard N, Roohafza H, Asgary S, Moattar F. “Barriers and facilitators of weight management in overweight and obese people: Qualitative findings of TABASSOM project”. Iran J Nurs Midwifery Res. 2012; 17(3):205-10.
207. Khosravi Boroujeni H, Sarrafzadegan N, Mohammadifard N, Sajjadi F, Asgari S, Maghroun M, Alikhassi H, Esmailzaded A. “The relation between dietary intake of vegetable oils and serum lipids and apolipoprotein levels in central Iran”. ARYA Atherosclerosis Journal 2012; 7(4): 168–175.
208. Garakyaraghi M, Kianjoo M, Mortazavi M, Sarrafzadegan N, Shemirani H, Shahparian M. “The efficacy of pharmaceutical combination of glucose, insulin, potassium, and magnesium along with thrombolytic therapy on the mortality of patients with acute myocardial infarction”. Arya Atherosclerosis Journal 2012;7(Suppl 5) :S36-S41.
209. Khaledifar A, Bahonar A, Asadilari M, Boshtam M, Gharipour M, Taghdisi MH, Sarrafzadegan N. “Risk factors of cardiovascular diseases in a worker population in Isfahan province (Isfahan Electricity Production and Distribution Company)”. Arya Atherosclerosis Journal 2012;7(Suppl 5) :S82-87.
210. Shimony A, Grandi SM, Pilote L, Joseph L, O’Loughlin J, Paradis G, Rinfret S, Sarrafzadegan N, Adamjee N, Yadav R, Gamra H, Diodati JG, Eisenberg MJ; for the ZESCA nvestigators. “Utilization of Evidence-Based Therapy for Acute Coronary Syndrome in High-Income and Low/Middle-Income Countries”. Am J Cardiol. 2014;113(5):793-7
211. Masoudkabir F, Sarrafzadegan N, Eisenberg MJ. “Effects of opium consumption on ardiometabolic diseases”. Nat Rev Cardiol 2013;10(12):733-40.
212. Eisenberg MJ, Grandi SM, Gervais A, O’Loughlin J, Paradis G, Rinfret S, Sarrafzadegan N, Sharma S, Lauzon C, Yadav R, Pilote L; ZESCA Investigators. “Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial”. J Am Coll Cardiol 2013;61(5):524-32.
213. Sadeghi M, Garakyaraghi M, Khosravi M, Taghavi M, Sarrafzadegan N, Roohafza H. “The impacts of cardiac rehabilitation program on echocardiographic parameters in coronary artery disease patients with left ventricular dysfunction”. Cardiol Res Pract. 2013. http://dx.doi.org/10.1155/2013/201713
214. Mohammadifard N, Nazem M, Sarrafzadegan N, Nouri F, Sajjadi F, Maghroun M, Alikhasi H. “Body mass index, waist-circumference and cardiovascular disease risk factors in Iranian adults: Isfahan Healthy Heart Program”. J Health Popul Nutr. 2013;31(3):388-97.
215. Gharipour M, Ramezani MA, Sadeghi M, Khosravi A, Masjedi M, Khosravi-Boroujeni H, Rafieian-Kopaei M, Sarrafzadegan N. “Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program”. J Res Med Sci. 2013;18(6):467-72.
216. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, Khosravi A. “Association between salt intake and Albuminuria in normotensive and hypertensive individuals. Int J Hypertens. 2013. doi: 10.1155/2013/523682.
217. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Tavakoli B, Tchernof A, Roohafza H, Sarrafzadegan N. “Association of apolipoprotein B, apolipoprotein A, and the its ratio with body fat distribution”. J Res Med Sci. 2013;18(4):326-9.
218. Mohammadifard N, Sarrafzadegan N, Mozaffarian D, Nazem M, Taheri M. “The relationship between nut consumption and blood pressure in an Iranian adult population: Isfahan Healthy Heart Program”. Yazdekhasti N Nutr Metab Cardiovasc Dis. 2013;23(10):929-36.
219. Haghighatdoost F, Sarrafzadegan N, Mohammadifard N, Sajjadi F, Maghroon M, Boshtam M, Alikhasi H, Azadbakht L. “Healthy eating index and cardiovascular risk factors among Iranians”. J Am Coll Nutr. 2013;32(2):111-21.
220. Sadeghi M, Shiri M, Roohafza H, Rakhshani F, Sepanlou S, Sarrafzadegan N. “Developing an appropriate model for self-care of hypertensive patients: first experience from EM RO”. ARYA Atheroscler. 2013;9(4):232-40.
221. Khosravi-Boroujeni H, Sarrafzadegan N, Mohammadifard N, Sajjadi F, Maghroun M, Asgari S, Rafieian-Kopaei M, Azadbakht L. “White rice consumption and CVD risk factors among Iranian population”. J Health Popul Nutr. 2013;31(2):252-61.
222. Alavi M, Irajpour A, Giles T, Rabiei K, Sarrafzadegan N. “Barriers to education in cardiac rehabilitation within an Iranian society: a qualitative descriptive study”. Contemp Nurse. 2013;44(2):204-14.
223. Talaei M, Sadeghi M, Marshall T, Thomas GN, Iranipour R, Nazarat N, Sarrafzadegan N. “Anthropometric indices predicting incident type 2 diabetes in an Iranian population: the Isfahan Cohort Study”. Diabetes Metab. 2013;39(5):424-31.
224. Mohammadifard N, Sarrafzadegan N, Ghassemi GR, Nouri F, Pashmi R. “Alteration in unhealthy nutrition behaviors in adolescents through community intervention: Isfahan Healthy Heart Program”. ARYA Atheroscler 2013;9(1):89-97.
225. Shokouh P, Joharimoghadam A, Roohafza H, Sadeghi M, Golabchi A, Boshtam M, Sarrafzadegan N. “Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial”. PPAR Res. 2013;2013:358074. doi: 10.1155/2013/358074
226. Gharipour M, Khosravi A, Sadeghi M, Roohafza H, Hashemi M, Sarrafzadegan N. “Socioeconomic characteristics and controlled hypertension: Evidence from Isfahan Healthy Heart Program”. ARYA Atheroscler. 2013;9(1):77-81.
227. Sarrafzadegan N, Gharipour M, Sadeghi M, Nouri F, Asgary S, Zarfeshani S. “Differences in the prevalence of metabolic syndrome in boys and girls based on various definitions”. ARYA Atheroscler. 2013;9(1):70-6.
228. Sarrafzadegan N, Rabiei K, Nouri F, Mohammadifard N, Moattar F, Roohafza H, Haghjooy Javanmard S, Zarfeshani S, Pourmoghaddas M. “Parental perceptions of weight status of their children”. ARYA Atheroscler. 2013;9(1):61-9.
229. Ahmadi A, Gharipour M, Nouri F, Sarrafzadegan N. “Metabolic syndrome in Iranian youths: a population-based study on junior and high schools students in rural and urban areas”. J Diabetes Res. 2013;738485.
230. Talaei M, Rabiei K, Talaei Z, Amiri N, Zolfaghari B, Kabiri P, Sarrafzadegan N. “Physical activity, sex, and socioeconomic status: A population based study”. ARYA Atheroscler. 2013;9(1):51-60.
231. Roohafza H, Sadeghi M, Shahnam M, Shokouh P, Teimori S, Amirpour A, Sarrafzadegan N. “Social norms of cigarette and hookah smokers in Iranian universities”. ARYA Atheroscler. 2013;9(1):45-50.
232. Gharipour M, Sarrafzadegan N, Sadeghi M, Andalib E, Talaie M, Shafie D, Aghababaie E. “Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio?”. Cholesterol. 2013;2013:198384. doi: 10.1155/2013/198384
233. Mohammadifard N, Toghianifar N, Sajjadi F, Alikhasi H, Kelishadi R, Maghroun M, Esmaeili M, Ehteshami S, Tabaie H, Sarrafzadegan N. “Improvement of dietary oil consumption following a community trial in a developing country: The role of translational research in health promotion”. ARYA Atheroscler. 2013;9(1):29-37.
234. Keyhani D, Kargarfard M, Sarrafzadegan N, Sadeghi M. “Autonomic function change following a supervised exercise program in patients with congestive heart failure”. ARYA Atheroscler. 2013;9(2):150-6.
235. Talaei M, Mohammadifard N, Khaje MR, Sarrafzadegan N, Sajjadi F, Alikhasi H, Maghroun M, Iraji F, Ehteshami S. “Healthy bread initiative: methods, findings, and theories–Isfahan Healthy Heart Program”. J Health Popul Nutr. 2013;31(1):49-57.
236. Sali R, Roohafza H, Sadeghi M, Andalib E, Shavandi H, Sarrafzadegan N. “Validation of the revised stressful life event questionnaire using a hybrid model of genetic algorithm and artificial neural networks”. Comput Math Methods Med. 2013;2013:601640. doi: 10.1155/2013/601640.
237. Haghighatdoost F, Sarrafzadegan N, Khosravi A, Noori F, Boshtam M, Mohammadifard N, Abdollhi Z, Azadbakht L. “Is the association between salt intake and blood pressure mediated by body mass index and central adiposity?”. Arch Iran Med. 2013;16(3):167-71.
238. Sarrafzadegan N, Khosravi-Boroujeni H, Esmaillzadeh A, Sadeghi M, Rafieian-Kopaei M, Asgary S. “The association between hypertriglyceridemic waist phenotype, menopause, and cardiovascular risk factors”. Arch Iran Med. 2013;16(3):161-6.
239. Roohafza H, Talaei M, Sadeghi M, Haghani P, Shokouh P, Sarrafzadegan N. “Opium decreases the age at myocardial infarction and sudden cardiac death: a long- and short-term outcome evaluation”. Arch Iran Med. 2013;16(3):154-60.
240. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Tavakoli B, Tchernof A, Roohafza H, Sarrafzadegan N. “Abdominal fat distribution and serum lipids in patients with and without coronary heart disease”. Arch Iran Med. 2013; 16(3):149-53.
241. Roohafza H, Sarrafzadegan N, Sadeghi M, Rafieian-Kopaei M, Sajjadi F, Khosravi-Boroujeni H. “The association between stress levels and food consumption among Iranian population”. Arch Iran Med. 2013;16(3):145-8.
242. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, Iranipour R. “Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study”. Arch Iran Med. 2013;16(3):138-44.
243. Askari G, Yazdekhasti N, Mohammadifard N, Sarrafzadegan N, Bahonar A, Badiei M, Sajjadi F, Taheri M. “The relationship between nut consumption and lipid profile among the Iranian adult population; Isfahan Healthy Heart Program”. Eur J Clin Nutr. 2013;67(4):385-9.
244. Sarrafzadegan N, Kelishadi R, Sadri G, Malekafzali H, Pourmoghaddas M, Heidari K, Shirani S, Bahonar A, Boshtam M, Asgary S, Mohammadifard N, Sadeghi M, Eshrati B, Hadipour E, Esmaillzadeh A, O’Loughlin J. “Outcomes of a comprehensive healthy lifestyle program on cardiometabolic risk factors in a developing country: the Isfahan healthy heart program.” Arch of Iran Med., 2013; 16(1):4-11.
245. Pourfarzam M, Movahedian A, Sarrafzadegan N, BasatiGh, Samsamshariat S.Z. “Association between Plasma Myeloperoxidase and Free 3-Nitrotyrosine Levels in Patients with Coronary Artery Disease”. International Journal of Clinical Medicine, 2013;4:158-164.
246. Sadeghi M, Ghashghaei FE, Rabiei K, Golabchi A, Noori F, Baboli MT, Sarrafzadegan N. “Does significant weight reduction in men with coronary artery disease manage risk factors after cardiac rehabilitation program?”. J Res Med Sci. 2013; 18(11):956-960.
247. Yazdekhasti N, Mohammadifard N, Sarrafzadegan N, Mozaffarian D, Nazem M, Taheri M. “The relationship between nut consumption and blood pressure in an Iranian adult population: Isfahan Healthy Heart Program”. Nutrition, Metabolism and Cardiovascular Diseases 2013; 23(10):929 – 936.
248. Gharipour M, Sadeghi M, Mansourian M, Andalib E, Talaie M, Mohamadifard N, Sarrafzadegan N. “Correlation of circulating inflammatory markers, ghrelin, adiponectin with obesity indices in subjects with metabolic syndrome”. Pakistan Journal of Medical Sciences 2013; 29(1):264-268.
249. Khosravi AR, Raoufi A, Pourmoghadas M, Paydari N, Gharipour M, Namdari M, Khaledifar A, Khosravi M, Bahonar A, Ostovan M, Hassanzadeh M.E, Sarrafzadegan N. “Late clinical events of drug eluting versus bare metal stenting; OPCES’ ancillary study”. Pakistan Journal of Medical Sciences 2013; 29(1):258-263.
250. Khosravi A, Noohi F, Andalib E, Sadeghiyan S, Peighambari M, Sarrafzadegan N. “Management of high blood pressure: The first Iranian high blood pressure guideline (summary)”. Iranian Heart Journal, 2013; 14(1):27-35.
251. Sarrafzadegan N, Sadeghi M, Gharipour M, Talaiei M, Shafie D, Aghababaie E. “Left Ventricular Diastolic Function in Subjects with Metabolic Syndrome: Isfahan Cohort Study”. Iranian Heart Journal, 2013; 13(4):63-77.
252. Arabzadeh S, Sadeghi M, Rabiei K, Sarrafzadegan N. “Factors affecting uncontrolled hypertension in an Iranian population”. Iranian Heart Journal 2013; 14(3).
253. Talaei M, Sadeghi M, Mohammadifard N, Shokouh P, Oveisgharan S, Sarrafzadegan N. “Incident hypertension and its predictors: the Isfahan Cohort Study”. J Hypertens 2014; 32(1):30-8.
254. Soltani R, Hakimi M, Asgary S, Ghanadian SM, Keshvari M, Sarrafzadegan N. “Evaluation of the effects of Vaccinium arctostaphylos L. fruit extract on serum lipids and hs-CRP levels and oxidative stress in adult patients with hyperlipidemia: a randomized, double-blind, placebo-controlled clinical trial”. Evidence-Based Complementary and Alternative Medicine 2014; DOI: 10.1155/2014/217451
255. Roohafza H, Sadeghi M, Naghnaeian M, Shokouh P, Ahmadi A, Sarrafzadegan N. “Relationship between metabolic syndrome and its components with psychological distress”. International Journal of Endocrinology 2014. http://dx.doi.org/10.1155/2014/203463
256. Rafiee L, Abedini M, Haghjooy Javanmard Sh, Sarrafzadegan N, Mansourian M. “Association of GSTT1 and GSTM1 polymorphisms with blood pressure: A Bayesian modeling of continuous data”. J Res Med Sci.2014; 19(3):200-204.
257. Sarrafzadegan N, Rabiei K, Abedi H, Kelishadi R, Fereydoun Mohaseli Kh, Alavi M, Roohafza H. “Indicators Developed to Evaluate the International Framework Convention on Tobacco Control in Iran; A Grounded Theory Study”. Iran J Med Sci. 2014; 39(2):213-217.
258. Sarrafzadegan N, Rabiei K, Wong F, Roohafza H, Zarfeshani S, Noori F, Grainger Gasser A. “The sustainability of interventions of a community-based trial on children and adolescents’ healthy lifestyle”. ARYA Atherosclerosis 2014;10(2):107-117.
259. Gharipour M, Sadeghi M, Dianatkhah M, Bidmeshgi Sh, Ahmadi A, Tahri M, Sarrafzadegan N. “The Cut-Off Values of Anthropometric Indices for Identifying Subjects at Risk for Metabolic Syndrome in Iranian Elderly Men”. Journal of Obesity 2014.
260. Arabzadeh S, Sadeghi M, Rabiei K, Sarrafzadegan N, Taheri L, Golshahi A. “Determinants of uncontrolled hypertension in an Iranian population”. ARYA Atherosclerosis 2014;10(1):25-31.
261. Sarrafzadegan N, Rabiei K, Fereydoun Mohaseli Kh, Manzouri L, Roohafza H, Kelishadi R, Abedi H, Azaripour Masooleh H, Alavi M, Heidari Gh. “Do Iranian tobacco growers support the World Health Organization framework convention on tobacco control?”. Journal of Education and Health Promotion 2014;3(1):32.
262. Dianatkhah M, Rahgozar M, Talaei M, Karimloua M, Sadeghi M, Oveisgharan S, Sarrafzadegan N. “Comparison of competing risks models based on cumulative incidence function in analyzing time to cardiovascular diseases”. ARYA Atherosclerosis 2014;10(1):6-12.
263. Gharipour M, Sarrafzadegan N, Sadeghi M, Khosravi M, Hoseini M, Khosravi-Boroujeni H. “The metabolic syndrome and associated lifestyle factors among the Iranian population”. Advance Biomedical Sciences 2014.
264. Ahmadi A, Gharipour M, Nouri F, Kelishadi R, Sadeghi M, Sarrafzadegan N. “Association between adolescence obesity and metabolic syndrome: Evidence from Isfahan Healthy Heart Program”. Indian Journal of Endocrinology and Metabolism 2014;18(4):569-573.
265. Gharipour M, Sadeghi M, Hosseini H, Andalib E, Bakhtiari Boroujeni M, Sarrafzadegan N. “Effect of age on phenotype of metabolic syndrome in developing country”. Advance Biomedical Sciences 2014.
266. Haghighatdoost F, Sarrafzadegan N, Mohammadifard N, Asgary S, Boshtam M, Azadbakht L. “Assessing body shape index as a risk predictor for cardiovascular diseases and metabolic syndrome among Iranian adults”. Nutrition 2014;30(6):636-44.
267. Basati Gh, Emami Razavi A, Abdi S, Sarrafzadegan N. “The importance of adipokines in relation to the inflammatory enzyme, myeloperoxidase in patients with coronary artery disease”. Acta Medica Iranica 2014.
268. Sadeghi M, Khosravi-Boroujeni H, Sarrafzadegan N, Asgary S, Roohafza H, Gharipour M, Sajjadi F, Khalesi S, Rafieian-kopaei M. “Cheese consumption in relation to cardiovascular risk factors among Iranian adults- IHHP Study”. Nutrition Research and Practice 2014;8(3):336-41.
269. Sadeghi M, Garakyaraghi M, Taghavi M, Khosravi M, Sarrafzadegan N, Roohafza H. “The impacts of cardiac rehabilitation program on exercise capacity, quality of life, and functional status of coronary artery disease patients with left ventricular dysfunction”. Rehabilitation Nursing – ID RNJ-13-02-000264.R1.
270. Toghianifar N, Sarrafzadegan N, Gharipour M, Rabiei K, Najafian J. “Comparison of quality of life scores between cigarette and hookah smokers: findings from Isfahan Healthy Heart Program (IHHP)”. Advances in Epidemiology 2014.
271. Mohammadian-Hafshejani A, Sarrafzadegan N, Hosseini Sh, Baradaran H, Roohafza H, Sadeghi M, Asadi-Lari M. “Seasonal pattern in admissions and mortality from acute myocardial infarction in elderly patients in Isfahan, Iran”. ARYA Atherosclerosis 2014; 10(1):46-54.
272. Gee M,Campbell N, Sarrafzadegan N, Jafar T, Khalsa T, Mangat B, Poulter N, Prabhakaran D, Sonkodi S, Whelton P, Woodward M, Zhang XH. “Standards for the uniform reporting of hypertension in adults using population survey data: Recommendations from the World Hypertension League Expert Committee”. Journal of Clinical Hypertension 2014;16(11):773-81.
273. Turk-Adawi K, Sarrafzadegan N, L. Grace Sh. “Global availability of cardiac rehabilitation”. Nat Rev Cardiol 2014;98:1-11.
274. Alfieri O, Mayosi BM, Park SJ, Sarrafzadegan N, Virmani R. “Exploring unknowns in cardiology”. Nat Rev Cardiol 2014; 11(11):664-670.
275. Sarrafzadegan N, Talaei M, Sadeghi M, Mohammadifard N, Taheri M, Lotfizadeh M, Esmaillzadeh A, Khosravi-Boroujeni H. “Determinants of weight change in a longitudinal study of Iranian adults: Isfahan Cohort Study”. Arch Iran Med. 2014; 17(8):539-44.
276. Samsam Shariat S.Z, Bolhasani M, Sarrafzadegan N, Najafi S, Asgary S. “Evaluation of relationship between blood Peroxidases activity and Visfatin levels in metabolic syndrome patients”. ARYA Atherosclerosis Journal 2014; 10(4):218-226.
277. Roohafza H, Kabir A, Sadeghi M, Shokouh P, Aalaei-Andabili H, Mehrabi Y, Sarrafzadegan N. “ Effect of psychological distress on weight concern and weight control behaviors.” Arch Iran Med. 2014;17(9):608-12
278. Roohafza H, Shokouh P, Sadeghi M, Alikhassy Z, Sarrafzadegan N. “A possible role for pioglitazone in the management of depressive symptoms in metabolic syndrome patients (EPICAMP study) -A double blind, randomized clinical trial”. International Scholarly Research Notices 2014.
279. Basati G1, Razavi AE, Abdi S, Sarrafzedegan N. “The association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease”. Biomark Med. 2014;8(3):405-12.
280. Mohammadifard N, Sarrafzadegan N, Paknahade Z, Nouri F. “Inverse association of legume consumption and dyslipidemia: Isfahan Healthy Heart Program”. J Clin Lipidol. 2014;8(6):584-93.
281. Mohammadifard N, Yazdekhasi N, Stangl GI, Sarrafzadegan N. “Inverse association between the frequency of nut consumption and obesity among Iranian population: Isfahan Healthy Heart Program”. European Journal of Nutrition 2014.
282. Sadeghi M, Talaei M, Zand I, Oveisgharan Sh, Iranipour R, Esteki Ghashghaei F, Sarrafzadegan N. “Heart rate and cardiovascular events: a nested case-control in Isfahan Cohort Study”. Arch Iran Med 2014; 17(9):633-7.
283. Toghyanifar N, Sarrafzadgan N. “Women’s attitude toward smoking: effect of a community-based intervention on smoking-related social norms”. Int J Evid Based Healthc. 2014; 12(4):262-6.
284. Asgary S, SamsamShariat SZ, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N. “Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population”. Diabetes Metab Syndr. 2014.
285. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, Majed M, Navabakhsh B, Khoshnia M, Jaafari E, Mohammadifard N, Malekzadeh F, Merat S, Sadeghi M, Naemi M, Etemadi A, Thomas GN, Sarrafzadegan N, Cheng K, Marshall T, Malekzadeh R. “Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial”. Eur J Prev Cardiol. 2014.
286. Roohafza H, Kabir A, Sadeghi M, Shokouh P, Aalaei-Andabili SH, Mehrabi Y, Sarrafzadegan N. “Effect of psychological distress on weight concern and weight control behaviors”. Arch Iran Med. 2014; 17(9):608-12.
287. Khosravi A, Pourheidar B, Sadeghi M, Moezzi M, Mousavi M, Hajiannejad A, Bidram P, Gharipour M, Shirani Sh, Golshahi J, Sarrafzadegan N. “Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran”. ARYA Atherosclerosis 2014; 10:6.
288. Sadeghi M, Talaei M, Oveisgharan Sh, Rabiei K, Dianatkhah M, Bahonar A, Sarrafzadegan N. “The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort”. Adv Biomed Res 2014;3:242.
289. Taheri L, Sadeghi M, Sanei H, Rabiei K, Arabzadeh S, Golshahi J, Afshar H, Sarrafzadegan N. “The relation between occupational exposure to lead and blood pressure among employed normotensive men. J Res Med Sci. 2014; 19(6):490-4.
290. Sarrafzadegan N, Gotay C. A year in Review“Advances in the Prevention of Cardiovascular Disease”. Nat Rev Cardiol 2014.
291. Namazi G, Jamshidi Rad S, Attar AM, Sarrafzadegan N, Sadeghi M, Naderi G, Pourfarzam M. “Increased membrane lipid peroxidation and decreased Na+/K+-ATPase activity in erythrocytes of patients with stable coronary artery disease”. Coron Artery Dis. 2014.
292. Namazi G, Pourfarzam M, Jamshidi Rad S, Movahedian Attar A, Sarrafzadegan N, Sadeghi M, Asa P. “Association of the total cholesterol content of erythrocyte membranes with the severity of disease in stable coronary artery disease”. Cholesterol. 2014.
293. Shamsipour M, Farzadfar F, Gohari K, Parsaeian M, Amini H, Rabiei K, Hassanvand MS, Navidi I, Fotouhi A, Naddafi K, Sarrafzadegan N, Mansouri A, Mesdaghinia A, Larijani B, Yunesian M.A. “Framework for exploration and cleaning of environmental data – Tehran air quality data experience”. Arch Iran Med. 2014;17(12):821-9.
294. Hosseini M , Sarrafzadegan N, Kelishadi R, Monajemi M, Asgary S, Molavi-e Vardanjani H. “Population-based metabolic syndrome risk score and its determinants: The Isfahan Healthy Heart Program”. J Res Med Sci. 2014.

National
295. Sarrafzadegan N, Rafiei M. The percentiles and means of serum lipids and body mass index. J Amoozesh & Darman 1993; 17:15-24.
296. Sarrafzadegan N. Investigating and follow up of the myocardial infarction patients. J Amoozesh & Darman 1994; 4:63-67.
297. Boshtam M, Dokhani Sh, Sarrafzadegan N. The amount of NaCl and fat in all types of cheese used in Isfahan by chemical analysis. J of Standard 1994; 7:15-24.
298. Boshtam M, Sarrafzadegan N. Defining the amount of salt in all types of bread used in Isfahan by chemical analysis. Teb-o-Tazkie 1994; 13, 14:12-15.
299. Shadzi Sh, Safaie Y, Sarrafzadegan N. The level of lipoproteins among children aged 3-14 of families with positive history of premature myocardial infarction in Isfahan. J of Cardiovascular Diseases 1994; 10:601-605.
300. Attari A, Sarrafzadegan N, Ghasemi GH. The stressful events occurring among Isfahan population since 5 years ago. J Mental Behavior 1995; 3:30-37.
301. Sarrafzadegan N, Tavassoli A, Mortazavi SMB, Alikhasi H et al. The knowledge, attitude and practice of Isfahan people concerning the risk factors of cardiovascular diseases. J of Nabz 1995; 5:18-23.
302. Sarrafzadegan N, Soleimani B. The relation between height and myocardial infarction. J of Cardiovascular Diseases 1995; 16:893-896.
303. Sarrafzadegan N, Tavassoli A, Hashemipoor M, Kelishadi R. Defining the blood pressure percentiles of Isfahan population. J of Isfahan Medical School 1996; 43:32-40.
304. Hashemipoor M, Kelishadi R, Sarrafzadegan N. Is measuring serum cholesterol essential in children? J of Isfahan Medical School 1996; 2:63-68.
305. Hashemipoor M, Kelishadi R, Sarrafzadegan N. The level of Serum lipids among children in Isfahan. J Shaheed Beheshti University of Medical Sciences 1996; 3:98-107.
306. Rafiei M, Boshtam M, Sarrafzadegan N. Hydrogenation process and change in fatty acids composition in hydrogenated oils. J Teb- O- Tazkie 1997; 26:20-25.
307. Tavassoli A, Sarrafzadegan N, et al. The relation between positive family history and hypertension in Isfahan population. J of Tehran University of Medical Sciences 1997; 6:86-93.
308. Hashemipour M, Kelishadi R, Sarrafzadegan N. The prevalence of coronary artery disease risk factors in children aged 2-14 in families with premature myocardial infarction. J of Tehran University of Medical Sciences 1997; 6:62-66.
309. Sarrafzadegan N, Tavassoli A, Rafiei M, et al. The Prevalence of hyperlipidemia among people over 19 years of age in Isfahan. J Mashhad University of Medical Sciences 1997; 53:60-67.
310. Sarrafzadegan N, Mohammadifard N, Rafiei M. The prevalence of high triglyceride & decreased high-density lipoprotein syndrome among people over 20 years of age in Isfahan population. J of Tehran University of Medical Sciences 1998; 2:49-56.
311. Maghsoodlou S, Sarrafzadegan N, et al. The effect of cardiac rehabilitation programs on exercise capacity of cardiac patients by the results of exercise stress test. J of Medical Council of Islamic Republic of Iran Tehran University of Medical Sciences 1998; 4:253-59.
312. Najafian J, Boshtam M, Sarrafzadegan N, Rafiei M, et al. The relation between CK-MB/CK activity index and serum magnesium and fibrinogen in myocardial infarction. J of Isfahan University of Med Sciences 1999; 3(4):314-318.
313. Sadeghi K, Sarrafzadegan N, Kargarfar M. The effect of cardiac rehabilitation on type A personality of myocardial infarction patients. Olimpic J 1999; 1,2(13):83-95.
314. Sajadi F, Sarrafzadegan N, Alikhasi H, Mohammadifard N, Abdar N. The prevalence of non-insulin dependent diabetes mellitus in Iran during 1976-1997. The Journal of Uremia University of Medical Sciences 1999; 10(2):129-137.
315. Farhad M, Moazzam E, Faghih-Imany E. Sarrafzadegan N. “A study of knowledge attitude and practice of general practitioners regarding risk factors of cardiovascular disease”. J of Isfahan University of Medical Sciences 1999; 3(4):286-89.
316. Sarrafzadegan N, Mohammadifard N, Soltan-Mohammad-Zadeh MS. Are the myocardial infarction risk factors the same in survived and dead patients? Iranian J Public Health 2000; 29(1-4):61-68.
317. Mohammedifard N, Sarrafzadegan N, Jalali, A, Alikhassi H, et al. Food and nutrient intake among adult of Isfahan, Iran. Iranian J Public Health 2000; 29(1-4):127-137.
318. Sadeghi K, Khalili A, Sarrafzadegan N, Boshtam M. Studying physical activity in Isfahan population. Iranian J Public Health 2000; 29(1-4):69-76.
319. Mohammedifard N, Mehrabiian F, Sarrafzadegan N. The Effect of modifying fat diet in pregnant and Lactant women on serum lipids of neonatal and infantile. J of Isfahan Medical Sciences 2001; 5(4):307-13.
320. Golshadi I, Ansari R, Asgary S, Sarrafzadegan N, Boshtam M, et al. Familiarizing with using herbal extracts in Isfahan province. J of Medicinal Plants 2002; 1(2):21-28.
321. Mohammadi Fard N, Sarrafzadegan N, Sadri Gh, Malek-Afzali H, Baghaei A, et al. Isfahan Healthy Heart Program: A community based interventional program for cardiovascular disease prevention & control, design, method and primary experiences. J of Isfahan University of Medical Sciences 2002; 7(1):1-8.
322. Mohammdifard N, Sarrafzadegan N, Sajadi F, et al. Effect of cardiac rehabilitation on serum lipid. J of Medical Council of Islamic Republic of Iran 2002; 20(3):199-205.
323. Boshtam M, Rafiei M, Sarrafzadegan N, et al. “Impact of Vitamin E on Type II Diabetic Patients”. Journal of Shahid Sadoughi University of Medical Sciences & Health Services 2003; 10(4):32-40.
324. Rafiei M, Boshtam M, Sarrafzadegan N. “Relation between Calcium & Blood Pressure in Isfahan Population”. Journal of Isfahan Medical School 2003; 20(67):57-64.
325. Behradmanesh S, Dehghan H, Tavassoli A, Sarrafzadegan N. “Assessment of cost-effectiveness of several strategies for early diagnosis in patients with acute nontraumatic atypical chest pain and nonconclusive electrocardiogram”. Journal of Isfahan Medical School 2003; 20(67):26-32.
326. Rafiei M, Boshtam M, Sarrafzadegan N, et al. “The correlation of 24-hr urinary sodium and potassium with blood pressure in adults of Isfahan city”. Journal of Tehran University of Medical Science 2003; 60(5):406-415.
327. Kelishadi R, Sadri GH, Sarrafzadegan N, et al. “Dyslipidemia in adolescents. IHHP-HHPC”. The Medical Journal of Semnan University 2003; 4(3-4):167-76.
328. Rafiei M. Boshtam M, Tafazoli Shayan F, Sarrafzadegan N, et al. “Prevalence of smoking in adolescents of Isfahan”. J Razi 2004; 15(10):18-26.
329. Mohammadifard N, Sarrafzadegan N, Nouri N, Baghery M. “The effect of passive smoking on acute myocardial infarction and it’s relationship with fibrinogen and serum lipids”. Daneshvar Journal 2004; (51):75-80.
330. Ashrafi F, Noorbakhsh M, Haghighi M, Naderi Gh, Poormoghadas M, Sadeghi M, Sarrafzadegan N. “A study of the relationship between coronary/carotid artery disease & breast vessels calcification”. Journal of Isfahan Medical School 2004; 22(74,75):37-43.
331. Mohammadifard N, Sarrafzadegan N, et al. “The effect of passive smoking on serum fibrinogen level”. J of Daneshvar 2004; 51:75-80.
332. Kelishadi R, Hashemipour M, Sarrafzadegan N. “Effect of some environmental factors on smoking and the consequences of smoking on major cardiovascular disease (CVD) risk factors in adolescents: Isfahan Healthy Heart Program-Heart Health Promotion from Childhood”. Journal of Medical Faculty Guilan University of Medical Sciences 2004; 13(50):74-80.
333. Naderi Gh, Sarrafzadegan N, Boshtam M et al. “The Situation of new risk factors of cardiovascular disease in urban population of Isfahan”. Journal of Kerman University of Medical Sciences 2004; 11(1):28-35.
334. Sarrafzadegan N, Baghaiei AM, Sadeghi M, Amin Zadeh A. “Factor Analysis of Metabolic Syndrome among Iranian Male Smokers”. Iran J Med Sci 2005; 30(2):55-58.
335. Bosham M, Rfiei M, Sarrafzadegan N, et al. “The relationship between serum vitamin D level coronary artery disease and the associated risk factors in female carpet weavers”. J of Qazvin University of Medical Science 2005; 35:44-52.
336. Eshrati B. Fotoohi A, Madjd-Zadeh SR, Sarrafzadegan N, Rahimi A, Mohammad K. “The effect of using Kalleh-Pache smoking & diabetes on myocardial infarction in Arak district of Iran: An extension of Isfahan healthy heart project”. Arak University Rahavard Danesh Journal 2007; 9(4):35-44.
337. Boshtam M, Rafiei M, Sadeghi K, Sarrafzadegan N. “The effect of Vitamin E Suplementation on Mild Hypertension”. Behbood J 2007; 1:1-6.
338. Alavi M, Rabiei K, Abedi H, Zarfeshani S, Sarrafzadegan N. “Some concepts of the qualitative evaluation of ac community-based health program”. Journal of Isfahan Medical School-special Issue in Health Promotion 2009; 529-539.
339. Rabiei K, Lahijan Zadeh A, Shishe Foroush M, Shirani Sh, Ghaderian M, Zarfeshani S, Sarrafzadegan N. “The change in awareness & perception in Isfahan urban society after the first pollution reduction maneuver in the city”. Journal of Isfahan Medical School-special Issue in Health Promotion 2009; 476-486.
340. Nazari B, Asgary S, Sarrafzadegan N, et al. “Determination of fatty acid profiles in ghee & olive oil with emphasis on trans fatty acids by gas chromatography”. Journal of Shahrekord University of Medical Sciences 2009; 10(4):57-63.
341. Sanei H, Kelishadi R, Sarrafzadegan N, et al. “Health Promotion of children of parents with premature cardiovascular disease through education of healthy lifestyle: Isfahan Healthy Heart Program- Heart Health Promotion from childhood”. Journal of Isfahan Medical School 2009; 27(94):180-188.
342. Sarrafzadegan N, Alavi M, Rabiei K, Abedi HA, Bahonar A, Zarfeshani S. “Management of an interventional community-based program based on information resulted from process evaluation; Isfahan Healthy Heart Program”. Health Information Management 2010; 7(3):303-313.
343. Roshdi Benam M, Sadeghi M, Sanei H, Mashayekhi R, Taheri Sh, Atapour A, Sarrafzadegan N, Rarnezani M A, Akhbari M R, Jafaripour I, Maleki F, Madadi R. “Evaluation of Fat Cell’s Size, Number and Their Mediators in Ischemic Heart Disease Patients”. Journal of Isfahan Medical School, 2010; 28(107):225-237.
344. Bahonar A, Shahnam M, Asadi-Lari M, Bashtam M, Gharipoor M, Taghdisi M, Sarrafzadegan N. “Risk factors of cardiovascular diseases among workers in Isfahan”. Iran Occupational Health Journal. 2010; 7(1):1-0.
345. Shafie D, Sadeghi M, Hashemi M, Heydarpour M, Talaei M, Aghababaei E, Sarrafzadegan N. “Evaluation of heart rate recovery & exercise capacity in individuals with & without metabolic syndrome”. Journal of Isfahan Medical School 2011; 28(115):1-11.
346. Sarrafzadegan N. “Global reduction in the age of cardiovascular disease occurrence”. Zahedan Journal of Research in Medical Sciences 2011; 13(1):2-3.
347. Jani N, Hasanzadeh Kashtli A, Kabiri P, Sarrafzadegan N, Esmaeilzade A. “10 Year Trend in Nutrition Journal Impact Indexes in the World”. Health System Research 2011; 7(1):53-60.
348. Nourbakhsh S, Sarrafzadegan N, Azadbakht L. “Studying the Effect of Soy Milk Consumption on Blood Pressure and Anthropometric Parameters in Overweight and Obesity Girls”. Health System Research 2011; 7(1):43-52.
349. Sadat Rajaei S, Zahedi M, Azadbakht L, Esmaeilzadeh A, Sarrafzadegan N. “Dietary Energy Density Associated with Metabolic Syndrome in Women”. Health System Research 2011; 6(4):613-625.
350. Azadbakht L, Farajian S, Barak F, Mir Aghajani M, Sarrafzadegan N, Esmaeilzadeh A. “The Relationship of Red Meat Intake with Metabolic Syndrome and CRP Plasma Concentration in Women”. Health System Research 2011; 6(4):666-675.
351. Alavi M, Abedi H, Rabiee K, Karimi M, Sarrafzadegan N. “Concept of the quality of the educational services in cardiac rehabilitation”. Iranian Journal of Nursing Research 2011; 6(20):6-16.
352. Gharipour M, Akhavan Tabib A, Toghianifar N, Tavassoli A, Gharipour A, Sarrafzadegan N. “The pattern of pharmacological treatment in subjects with metabolic syndrome: Findings from Isfahan Healthy Heart Program”. Journal of Isfahan Medical School 2011; 29(138):1-9.
353. Sarrafzadegan N, Asgary S, Toghianifar N, Talaei M, Tavassoli A, Boshtam M, Sadeghi M. “Association of Apolipoprotein-A, B and Trans Fatty Acids with Cardiovascular Events: Isfahan Cohort Study”. Journal of Isfahan Medical School 2011; 28(124):1967-1977.
354. Sadeghi M, Sanei H, Hekmatnia A, Tavakoli B, Boshtam M, Khark M, Sarrafzadegan N. “Evaluation between fat distribution in abdominal CT scan with some physical and biochemical variable in Ischemic patients: GAAMI Study”. Journal of Isfahan Medical School, 2011; 124(28),:1-10.
355. Jani N, Hassanzadeh Keshteli A, Kabiri P, Sarrafzadegan N, Esmaillzadeh A. “10 Year Trend in Nutrition Journal Impact Indexes in the World”. Journal of Health System Research. 2011;1:53-90.
356. Golabchi A, Sarrafzadegan N, Pourmoghadas M, Shamsi I, Kazemi SA. “A syndrome that mimicking acute myocardial infarction: A case report”. Journal of Isfahan Medical School 2011;29(140): 651-656.
357. Kazemi SA, Sadeghi M, Hashemi SM, Heidari R, Gharipour M, Golabchi A, Sarrafzadegan N. “Evaluating the relation between metabolic syndrome and its components with low ankle to brachial index in an Iranian population”. Journal of Isfahan Medical School 2011;28(122):1724-1732.
358. Saeedi A, Sadeghi M, Saneie H, Ramezani M, Sarrafzadegan N. “The Comparison of serum inflammatory markers E-selection and Interlokin-6 in patient with acute coronary syndrome and stable angina”. ISMJ. 2011; 14 (3):151-158.
359. Najafpour Boushehri S, Mohammad Yusofi R, Mohammad Taib MN, Yassin Z, Sarrafzadegan N, Mirzaei K, Yazdekhasti N. “Effect of Vitamin Supplementation on Serum Oxidised Low-Density Lipoprotein Levels in Male Subjects with cardiovascular disease Risk Factors”. Iranian Journal of Basic Medical Sciences 2012; 15(4):952-958.
360. Sadeghi M, Aghdak P, Dehghan Naseiri, Gaheri R, Sarrafzadegan N. “Comparison of cardiovascular risk factors and healthy lifestyle housewives and working in central Iran _ Isfahan Healthy Heart Program”. Journal of Lorestan University of Medical Sciences 2012;13(4):55-64.
361. Sarrafzadegan N, Rabiei K, Sadeghi M, Gharipour M, et al. “The outcome of secondary prevention interventions in a community based interventional Program: Isfahan Healthy Heart program”. Yafteh 2012;14(1):55-68.
362. Mohammadian Hafshejani AB, Baradaran H, Sarrafzadegan N, AsadiLari M, Ramezani A, Hosseini SH, AllahBakhshiHafshejani F. “Predicting Factors of Short-term Survival in Patients with Acute Myocardial Infarction in Isfahan Using a Cox Regression Model”. Iranian Journal of Epidemiology 2012; 8(2): 31-36.
363. Mohammadian Hafshejani A, Baradaran Atarmoghaddam HR, Sarrafzadegan N. “Evaluation of short-term survival of patients with acute myocardial infarction and the differences between the sexes in Isfahan and Najaf Abad between (1378-1387). Razi Journal of Medical Sciences 2012;19(95):26-34.
364. Gharipour M, Kelishadi R, Khosravi A, Shirani Sh, Masjedi M, Sarrafzadegan N. “The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007”. Arch Med Sci 2012; 6.
365. Sarrafzadegan N, Kelishadi R, Rabiei K, Abedi H, Fereydoun Mohaseli Kh, Azaripour Masooleh H, Alavi M, Heidari Gh, Ghaffari M, O’Loughlin J. “A comprehensive model to evaluate implementation of the world health organization framework convention of tobacco control”. Iranian Journal of Nursing and Midwifery Research. 2012; 17(3):244-254.
366. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Sarrafzadegan N. “Is Subcutaneous Fat Tissue Associated with Coronary Artery Disease?”. Iranian Journal of Endocrinology and Metabolism, 2012; 14(2): 150-155.
367. Sarrafzadegan N, Sadeghi M, Paidarei N, Abadi E, Forouzani A, Hashemi M, Talaei M. “Metabolic Syndrome and Structural and Functional Echocardiographic Characteristics: A Case Control Study in Isfahan Cohort Study”. Iranian Journal of Endocrinology & Metabolism 2012;13(Suppl.6) :658-665.
368. Mohammadian Hafshejani A, Oveisgharan Sh, Sarrafzadegan N. “The Most Frequent and Fatal Types of Acute Myocardial Infarction in Isfahan, Iran”. Journal of Isfahan Medical School, 2013; 30(216):1-4.
369. Heidari Z, Azadbakht L, Feizi A, Sarrafzadegan N, Mohammadifard N. “Assessment of the distribution of usual intake of nutrients and estimating prevalence of intake deficiency and excess in a general over 40-years of age population of central region of Iran: Application of the National Cancer Institute (NCI) method”. Journal of Isfahan Medical School, 2013; 31(242):954-972.
370. Sadeghi M, Taheri L, Golshahi J, Rabiei K, Sarrafzadegan N. “Left Ventricular Echocardiographic Variables in Occupational Exposure to Lead”. Journal of Isfahan Medical School 2014; 32(297).
371. Hakimi M, Soltani R, Keshvari M, Asgari S, Sarrafzadegan N. “The effects of Vaccinium arctostaphylos on lipid profile in mild hyperlipidemia patients- a randomized clinical trial”. Journal of Shahrekord University of Medical Sciences 2014; 16(5): 92-99.

Under Review Manuscripts:
International and National Peer-Reviewed Journals
1. Sadeghi M, Gharipour M, Sarrafzadegan N, Shafie D, Aghababaie E. “Alteration of maximum heart rate in metabolic syndrome”. Journal of Diabetes Research.
2. Sadeghi M, Jamshidi rad S, Pourfarzam M, Movahedian A, Sarrafzadegan N, Asa P, Merasi M, Rajati M, Taghavi Saloot M, Namazi Gh. “Erythrocyte membrane lipid peroxidation in patients with coronary artery disease”. AIM Athero Special Issue.
3. Zand I, Talaei M, Sadeghi M, Oveisgharan Sh, Iranipour R, Esteki Ghashghaei F, Sarrafzadegan N. “Heart rate and cardiovascular events: A nested case-control in Isfahan Cohort Study”. AIM Athero Special Issue.
4. Gharipour M, Sadeghi M, Ghassemi GH, Bakhtiari-boroujeni M, Iraj B, Jozan M, Sarrafzadegan N. “Is socioeconomic status related to fasting plasma glucose in diabetic patients”. AIM Athero Special Issue.
5. Gharipour M, Sadeghi M, Ghassemi Gh, Jozan M, Bakhtiari boroujeni M, Iraj B, Sarrafzadegan N. “Socioeconomic disparities and controlling fasting plasma glucose in diabetic patients”. Acta Biomedica.
6. Haidary Sardabi E, Majoor Z, Sadeghi M, Pourmoghadas M, Bahonar A, Sarrafzadegan N. “Association between the threshold sensitivity to salty taste and level of blood pressure salt-sensitivity in young Iranian normotensive individuals”. ARYA Atherosclerosis
7. Behnemoon M, Sadeghi M, Garakyaraghi M, Koushkzari M, Naghnaian M, Sarrafzadegan N. “Association between air pollutants and heart failure symptom exacerbation leading to hospitalization”. Accepted in ARYA Atherosclerosis
8. Roohafza H, Khani A, Sadeghi M, Bahonar A, Sarrafzadegan N. “Health Volunteers’ Knowledge of Cardiovascular Diseases Prevention and Healthy Lifestyle after Six Years Community-trial: Isfahan Healthy Heart Program”. Journal of Education and Health Promotion. (accepted)
9. Roohafza H, Heidari K, Alinia T, Omidi R, Sadeghi M, Andalib E, Ajami A, Sarrafzadegan N. “Prevalence and motivational causes of smoking (cigarette and waterpipe) among Iranian adolescence; Results of ITUPP study”. The Scientific World Journal.
10. Gharipour M, Khosravi A, Gharipour A, Ahmadi A, Sarrafzadegan N. “The value of salt intake to predict metabolic syndrome: A population base study in Iran”. (Endocrinology Journal)
11. Heidari Z, Azadbakht L, Sarrafzadegan N, Maghroun M. “Usual intake distribution of minerals and prevalence of inadequacy in a large sample of Iranian at risk population: Application of NCI method”. International Journal of Food Sciences and Nutrition.
12. Soltani R, Keshvari M, Zolghadr M, Asgary S, Sahebkar A, Sarrafzadegan N. “Protective Effects of Hibiscus Sabdariffa on Metabolic Syndrome : a randomized, double-blind, placebo-controlled clinical trial”.
13. Asgary S, Movahedian A, Sahebkar A, Taleghani M, Badiee A, Sarrafzadegan N. “Lead , Mercury and Cadmium in Relation to Coronary Artery Disease”. Shahrekord University of Medical Sciences.
14. Sarrafzadegan N, Salehi-Abargouei A, Lotfizadeh M, Khosravi-Boroujeni H. “Magnesium and the metabolic syndrome: a systematic review and meta-analysis”. Nutrition Journal 2014.
15. Khosravi AR, Mohammadifard N, Sarrafzadegan N. “Validation of spot urine method with standard 24hours urine collection test to determine urinary sodium excretion: Results from Isfahan Salt Study”. Preventing Chronic Disease J. 2014.
16. Sadeghi M, Talaei M, Parvaresh E, Dianatkhah M, Oveisgharan Sh, Sarrafzadegan N. “Determinants of incident prediabetes and type 2 diabetes in a 7-year cohort in a developing country: The Isfahan Cohort Study”. Journal of Diabetes.
17. Asgay S et al. “Evaluation of the effects of Cornus mas L. fruit extract on glycemic control and insulin level in type 2 diabetic adult patients: a randomized, double-blind, placebo-controlled clinical trial”. Indian Journal of Medical Research 2014.
18. Mousavi M, Sadeghi M, Porheidar B, Bidram P, Naderi Boldaji R, Bahonar A, Heidari E, Mahjoor Z, Sarrafzadegan N. “Association of positive family history for hypertension and salt sensitivity of blood pressure in normotensive individuals”.Iranian Heart Journal.
19. Sarrafzadegan N, Rabiei K, Alavi M, Golshahi J, Kelishadi R, et al. “Policy makers’ viewpoints about implementation of the WHO-Framework Convention on Tobacco Control in Iran: A qualitative investigation on the program facilitators”. Slovenian Journal of Public Health.

Principle Investigator (PI) or CO-PI or Collaborator in International Studies/Grants:
1. Zyban as an effective smoking cessation aid for patients following an acute coronary syndrome, The ZESCA Trail. McGill University, Jewish General Hospital, Montreal/Canada. (National PI) 2004-2008
2. Strengthening the links between research, practice and public policy to reduce the burden of tobacco, ICE Grant. McGill and Montreal Universities, Montreal/Canada. (Collaborator) 2004-2006
3. Prevention of recurrent myocardial infarction & stroke. (WHO PREMIS Study). The World Health Organization, Geneva/Switzerland. (National PI) 2002-2005
4. The International Antismoking Campaign, Quit & Win. National Public Health Institute, Helsinki/Finland. (National PI) 1998-2006
5. Assessment of Cost-Effectiveness of several strategies of early diagnosis in patients with acute chest pain and non-conclusive Electerocardiogram (ASSENCE Trial) Udine University, Udine/Italy. (National PI) 1998-2000
6. Word Pacing Survey, Sydney, Australia, Sydney/Australia. 1998-2000
7. International Task Force for Coronary Heart Disease Prevention and Control, Munster/Germany. 1999-2005
8. Genetic polymorphism of the caucasus population and their geographic neighbors on the mollecular level, Liepzic/Germany. (P.I) 2001-2003
9. Seed Grant from World Health Organization, the United Nations Foundation for “Comprehensive Tobacco Control & Prevention Program Among Iranian Women & Adolescent” Project. CDC, Atlanta/USA. (PI) 2000-2001
10. Global Health Professional Survey of the World Health Organization and Iranian Heart Foundation, (WHO Study). The World Health Organization, Geneva/Switzerland. (National PI) 2001-2003
11. Physician Hypertension Survey. The Eastern Mediterranean Network on Heart Health. 2002
12. WHO Grant for the Evaluation of “Isfahan Healthy Heart Programme”, a Community-based Program for Chronic Disease Prevention and Control, WHO, Geneva /Switzerland. (P.I) 2002-2003
13. Studying the “Genetics of Premature Coronary Heart Disease”, Yale University, New Haven /USA. 2004-2006
14. COBALT Study (Correlation between abdominal obesity, lipoproteins and transfatty aids), Isfahan Cardiovascular Research Center and Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal/Canada. (P.I) 2005-2007
15. WHO Risk Prediction Chart for Predicting Cardiovascular Diseases, WHO, Geneva, Switzerland. (P.I) 2005-2007
16. GAAMI Study (Gluteal – abdominal adipocyte morphology in ischemic patients) Isfahan Cardiovascular Research Center and Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal/Canada. (PI) 2006-2008
17. Apolipoproteins B & A Standardization with North-West Lipid Metabolism and Diabetes Research Laboratories, Washington DC, USA. 2006
18. Glycemic index & glycemic load as risk factors of type 2 diabetes Mellitus in Iranian Population, Gent University, Belgium. (Co-Supervisor) 2007
19. World Heart Federation Children’s Project Micro-Grant on Sustainability, World Heart Federation, Switzerland. (National PI) 2010
20. Designing a Suitable Advocacy Package for Salt Consumption Rreduction at the Population Level & High Risk Groups, World Health Organization (WHO) Grant. (PI) 2011-2012
21. Developing “Suitable Model for Self Care of Cardiac Patients”. WHO Grant. (PI) 2011-2012
22. International Atherosclerosis Society/Pfiezer Grant on Dyslipidemia , International Atherosclerosis Society. (PI) 2013-2015
23. “Smoking Prevention and Cessation Interventions in Low and Middle Income Countries” by McGiLL University,Montreal,Quebec, Canada.(CO-PI) 2014
24. “Intensive Medical Treatment of Angina with Normal Angiography (IMT)”,Cardiology Division, Vancouver General Hospital,BC,Canada.(CO-PI 2014
25. “Validity and Reproducibility of Food Frequency Questionnaire for Assessment of Sodium/Salt Intake, Food Group Contribution in Sodium/Salt Intake”, Ministry of Health, Iran. (PI) 2013-2015
26. Development of “A Five Years Multi Sectorial National Action Plan for Salt Intake Reduction”, World Health Organization WHO Grant.(PI) 2014
27. “Design & Implementation of National Registry of Cardiovascular Disease & Coronary Interventions”. Ministray of Health,Tehran, Iran.(PI) 2014-2018
28. “Cardiac Rehabilitation Delivery Model for Low-resource Settings: A consensus Statement”.York University, Toronto, Canada. (Vice-Chair of primary writing panel) 2013-2016
29. “Assessing the Feasibility of Running a Cardiac Rehabilitation Program in a middle-income Country”. York University, Toronto, Canada. (Collaborator) 2015